

04/15/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A

Applicants: Olaf Schneewind et al.
Docket: 510015.213
Title: IDENTIFICATION OF SORTASE GENE

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL270921369US

Date of Deposit: April 15, 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By:

Name: Suzie J. McCleave

jc530 U.S. PTO
09/292437
04/15/99

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.
- ☒ Utility Patent Application: Spec. 70 pgs; 97 claims; Abstract 1 pg.
The fee has been calculated as shown below in the 'Claims as Filed' table.
- ☒ 14 sheets of informal drawings
- ☒ An unsigned Declaration
- ☒ A check in the amount of \$1463.00 to cover the Filing Fee
- ☒ Small entity status to be established at a later date
- ☒ Sequence Listing in paper and computer readable form: The undersigned hereby certifies under 37 C.F.R. 1.821 (f) that the information recorded in the computer readable form is identical to the written sequence listing.
- ☒ Return postcard

CLAIMS AS FILED

Number of Claims Filed	In Excess of:	Number Extra	Rate	Fee
Basic Filing Fee				\$380.00
Total Claims				
97	20	77	x 9.00	= \$693.00
Independent Claims				
13	3	10	x 39.00	= \$390.00
MULTIPLE DEPENDENT CLAIM FEE				\$0.00
TOTAL FILING FEE				\$1463.00

Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230. A duplicate of this sheet is enclosed.

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East, 38th Floor
Los Angeles, California 90067-3024
(310) 788-5000

By:

Name: Michael B. Farber
Reg. No.: 32,612
Initials: MBF/sjm

IDENTIFICATION OF SORTASE GENE

GOVERNMENT RIGHTS

This invention was made with Government support under Grant No. AI39987, awarded by the National Institutes of Health. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

This invention is directed to an enzyme from Gram-positive bacteria, designated sortase-transamidase, nucleic acid segments encoding the enzyme, and methods of use of the enzyme.

Human infections caused by Gram-positive bacteria present a medical challenge due to the dramatic increase in multiple antibiotic resistance strains in recent years. Gram-positive bacteria that can cause serious or fatal infections in humans include *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Pneumococcus*, *Bacillus*, *Actinomyces*, *Mycobacterium*, and *Listeria*, as well as others. Infections caused by these pathogens are particularly severe and difficult to treat in immunologically compromised patients. These include patients suffering from infection with the Human Immunodeficiency Virus (HIV), the virus that causes AIDS, as well as patients given immune-suppressive agents for treatment of cancer or autoimmune diseases. In particular, infections caused by various *Mycobacterium* species, including *M. tuberculosis*, *M. bovis*, *M. avium*, and *M. intracellulare*, are frequently the cause of disease in patients with AIDS.

Therefore, it is apparent that new target sites for bacterial chemotherapy are needed if such pathogenic organisms are to be controlled.

A unique characteristic of these pathogens and many Gram-positive bacteria is their surface display of proteins anchored to the cell wall. In fact, many of these molecules are known to be involved in essential cellular functions, including pathogenesis in a susceptible host.

Thus, a possible disruption in this anchoring process may prove to be an effective treatment against these disease-causing elements.

The anchoring of surface molecules to the cell wall in Gram-positive bacteria has been demonstrated to involve a conserved pathway, culminating in recognition of a conserved cleavage/anchoring site by some previously uncharacterized cellular machinery. Molecules whose ultimate location is the cell wall must invariably be translocated across the single cellular membrane of these organisms. This is mediated for all cell wall anchored proteins by the well studied secretory pathway, involving cleavage of an amino-terminal signal peptide by a type I signal peptidase. Upon translocation of the molecule out of the cytoplasm, a mechanism must be present that extracellularly recognizes this protein as a substrate for anchoring. This process has been previously shown to involve the carboxyl-terminally located cell wall sorting signal, consisting of a highly conserved motif such as LPXTG (SEQ ID NO:1), in which X can represent any of the twenty naturally occurring L-amino acids, followed by a series of hydrophobic residues and ultimately a sequence of positively-charged residues. Thus, once amino-terminally modified and successfully secreted, a polypeptide with this carboxyl-terminal sequence can present itself as a substrate to be processed by the anchoring machinery. At this time, cleavage of the sorting signal after the threonine residue is coupled with covalent linkage of the remainder of the polypeptide to the free amino group of the pentaglycine crossbridge in the cell wall.

It is this transpeptidation reaction that anchors mature surface proteins to the peptidoglycan layer, from which point the molecules can serve their biological functions. Therefore, there is a need to isolate and purify the enzyme that catalyzes this reaction. There is also a need to identify the gene encoding such an enzyme in order that the enzyme can be produced by genetic engineering techniques. There is also a need to identify compounds that interfere with surface protein anchoring by inhibiting sortase.

Additionally, there is also a need to develop new methods for displaying proteins or peptides on the surfaces of bacteria. For many purposes, it is desirable to display proteins or peptides on the surfaces of bacteria so that the proteins or peptides are accessible to the

surrounding solution, and can, for example, be bound by a ligand that is bound specifically by the protein or peptide. In particular, the display of proteins on the surface of bacteria is desirable for the preparation of vaccines, the linkage of molecules such as antibiotic molecules or diagnostic reagents to cells, for screening reagents such as monoclonal antibodies, and for the selection of cloned proteins by displaying the cloned proteins, then observing their reaction with specific reagents such as antibodies. One way of doing this has been with phage display (G.P. Smith, "Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface," Science 228:1315-1316 (1985)). However, phage display is limited in its practicality, because it requires that the protein being displayed to be inserted into a coat protein of filamentous phage and retain its activity while not distorting the conformation of the coat protein, allowing functional virions to be formed. In general, this technique is therefore limited only to small peptide and proteins.

Therefore, there is a need for a more general method of peptide and protein display.

SUMMARY

The present invention is directed to sortase-transamidase enzymes from Gram-positive bacteria, particularly the products of the surface protein sorting (*srtA*) gene of *Staphylococcus aureus*, and methods for their use, particularly in the areas of drug screening and peptide and protein display.

One aspect of the present invention is a substantially purified sortase-transamidase enzyme from a Gram-positive bacterium, the enzyme catalyzing a reaction that covalently cross-links the carboxyl terminus of a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, the sorting signal having a motif of LPX₃X₄G therein, wherein sorting occurs by cleavage between the fourth and fifth residues of the LPX₃X₄G motif. Typically, the Gram-positive bacterium is a species selected from the group consisting of but not limited to *Staphylococcus aureus*, *S. sobrinus*, *Enterococcus faecalis*, *Streptococcus pyogenes*, and *Listeria*

monocytogenes. Preferably, the Gram-positive bacterium is *S. aureus*, and more preferably, the enzyme is the product of the *srtA* gene of *S. aureus*.

Preferably, the enzyme has a molecular weight of about 23,539 daltons and the sorting signal further includes: (2) a substantially hydrophobic domain of at least 31 amino acids
5 carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine.

10 Preferably, the enzyme includes an amino acid sequence of: (1) M-K-K-W-T-N-R-L-M-T-I-A-G-V-V-L-I-L-V-A-A-Y-L-F-A-K-P-H-I-D-N-Y-L-H-D-K-D-K-D-E-K-I-E-Q-Y-D-K-N-V-K-E-Q-A-S-K-D-K-K-Q-Q-A-K-P-Q-I-P-K-D-K-S-K-V-A-G-Y-I-E-I-P-D-A-D-I-K-E-P-V-Y-P-G-P-A-T-P-E-Q-L-N-R-G-V-S-F-A-E-E-N-E-S-L-D-D-Q-N-I-S-I-A-G-H-T-F-I-D-R-P-N-Y-Q-F-T-N-L-K-A-A-K-K-G-S-M-V-Y-F-K-V-G-N-E-T-R-K-Y-K-M-T-S-I-R-D-V-K-
15 P-T-D-V-G-V-L-D-E-Q-K-G-K-D-K-Q-L-T-L-I-T-C-D-D-Y-N-E-K-T-G-V-W-E-K-R-K-I-F-V-A-T-E-V-K (SEQ ID NO: 3) and (2) sequences incorporating one or more conservative amino acid substitutions in SEQ ID NO:3, wherein the conservative amino acid substitutions are any of the following: (1) any of isoleucine, leucine, and valine for any other of these amino acids; (2) aspartic acid for glutamic acid and vice versa; (3) glutamine for asparagine and vice versa; and
20 (4) serine for threonine and vice versa.

Another aspect of the present invention is a nucleic acid sequence encoding this enzyme. In one alternative, the nucleic acid sequence includes therein a sequence of: (1)
ATGAAAAAATGGACAAATCGATTAATGACAATCGCTGGTGTGGTACTTATCCTAGTG
GCAGCATATTTGTTTGCTAAACCACATATCGATAATTATCTTCACGATAAAGATAAA
25 GATGAAAAGATTGAACAATATGATAAAAATGTAAAAGAACAGGCGAGTAAAGATA
AAAAGCAGCAAGCTAAACCTCAAATTCCGAAAGATAAATCGAAAGTGGCAGGCTAT
ATTGAAATTCCAGATGCTGATATTAAAGAACCAGTATATCCAGGACCAGCAACACCT
GAACAATTAAATAGAGGTGTAAGCTTTGCAGAAGAAAATGAATCACTAGATGATCA

AAATATTTCAATTGCAGGACACACTTTCATTGACCGTCCGAACATCAATTTACAAA
TCTTAAAGCAGCCAAAAAAGGTAGTATGGTGTACTTTAAAGTTGGTAATGAAACAC
GTAAGTATAAAATGACAAGTATAAGAGATGTTAAGCCTACAGATGTAGGAGTTCTA
GATGAACAAAAAGGTAAAGATAAACAATTAACATTAATTACTTGTGATGATTACAA
5 TGAAAAGACAGGCGTTTGGGAAAAACGTAAAATCTTTGTAGCTACAGAAGTCAAAT

AA (SEQ ID NO: 2); and (2) a sequence complementary to SEQ ID NO: 2. In another
alternative, the nucleic acid sequence can include a sequence hybridizing with SEQ ID NO: 2 or
a sequence complementary to SEQ ID NO: 2 with no greater than about a 15% mismatch under
stringent conditions. Preferably, the degree of mismatch is less than about 5%; more preferably,
10 the degree of mismatch is less than about 2%.

Yet another aspect of the present invention is a vector comprising the nucleic acid
sequence of the present invention operatively linked to at least one control sequence that controls
the expression or regulation of the nucleic acid sequence.

Yet another aspect of the present invention is a host cell transfected with a vector
15 of the present invention.

Another aspect of the present invention is a method for producing a substantially
purified sortase-transamidase enzyme. The method comprises the steps of:

(1) culturing a host cell according to the present invention under conditions in
which the host cell expresses the encoded sortase-transamidase enzyme; and

20 (2) purifying the expressed enzyme to produce substantially purified sortase-
transamidase enzyme.

Another aspect of the present invention is a method for screening a compound for
anti-sortase-transamidase activity. This method is important in providing a way to screen for
antibiotics that disrupt the sorting reaction and are likely to be effective in treating infections
25 caused by Gram-positive bacteria.

In one alternative, the screening method comprises the steps of:

(1) providing a substantially purified sortase-transamidase enzyme according to
the present invention;

(2) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

(3) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

5 In another alternative, the screening method comprises the steps of:

(1) providing an active fraction of sortase-transamidase enzyme from a Gram-positive bacterium;

(2) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

10 (3) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

The active fraction of sortase-transamidase activity can be a particulate fraction from *Staphylococcus aureus* or another Gram-positive bacterium.

15 The assay for sortase-transamidase enzyme can be performed by monitoring the capture of a soluble peptide that is a substrate for the enzyme by its interaction with an affinity resin. In one alternative, the soluble peptide includes a sequence of at least six histidine residues and the affinity resin contains nickel. In another alternative, the soluble peptide includes the active site of glutathione S-transferase and the affinity resin contains glutathione. In yet another alternative, the soluble peptide includes the active site of streptavidin and the affinity resin
20 contains biotin. In still another alternative, the soluble peptide includes the active site of maltose binding protein and the affinity resin contains amylose.

Still another aspect of the present invention is an antibody specifically binding the sortase-transamidase enzyme of the present invention.

25 Yet another aspect of the present invention is a protein molecule comprising a substantially purified sortase-transamidase enzyme according to the present invention extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column through the histidine residues added at the carboxyl-terminus.

Still another aspect of the present invention is a method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(1) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (a) a motif of LPX_3X_4G therein; (b) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (c) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(2) forming a reaction mixture including: (i) the expressed polypeptide; (ii) a substantially purified sortase-transamidase according to the present invention; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(3) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

Another display method according to the present invention comprises:

(1) cloning a nucleic acid segment encoding a chimeric protein into a Gram-positive bacterium to generate a cloned chimeric protein including therein a carboxyl-terminal sorting signal as described above;

(2) growing the bacterium into which the nucleic acid segment has been cloned to express the cloned chimeric protein to generate a chimeric protein including therein a carboxyl-terminal sorting signal; and

(3) binding the polypeptide covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX_3X_4G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand.

Another aspect of the present invention is a polypeptide displayed on the surface of a Gram-positive bacterium by covalent linkage of an amino-acid sequence of LPX₃X₄ derived from cleavage of an LPX₃X₄G motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine, the polypeptide being displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand.

Another aspect of the present invention is a covalent complex comprising:

- (1) the displayed polypeptide; and
- (2) an antigen or hapten covalently cross-linked to the polypeptide.

Yet another aspect of the present invention is a method for vaccination of an animal comprising the step of immunizing the animal with the displayed polypeptide to generate an immune response against the displayed polypeptide, or, alternatively, with the covalent complex to generate an immune response against the antigen or the hapten.

Still another aspect of the present invention is a method for screening for expression of a cloned polypeptide comprising the steps of:

- (1) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end as described above;
- (2) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) a substantially purified sortase-transamidase enzyme according to the present invention; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;
- (3) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and
- (4) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

Still another aspect of the present invention is a method for the diagnosis or treatment of a bacterial infection caused by a Gram-positive bacterium comprising the steps of:

(1) conjugating an antibiotic or a detection reagent to a protein including therein a carboxyl-terminal sorting signal as described above to produce a conjugate; and

5 (2) introducing the conjugate to an organism infected with a Gram-positive bacterium in order to cause the conjugate to be sorted and covalently cross-linked to the cell walls of the bacterium in order to treat or diagnose the infection.

If an antibiotic is used, typically it is a penicillin, ampicillin, vancomycin, gentamicin, streptomycin, a cephalosporin, amikacin, kanamycin, neomycin, paromomycin, 10 tobramycin, ciprofloxacin, clindamycin, rifampin, chloramphenicol, norfloxacin, or a derivative of these antibiotics.

Similarly, another aspect of the present invention is a conjugate comprising an antibiotic or a detection reagent covalently conjugated to a protein including therein a carboxyl-terminal sorting signal as described above to produce a conjugate. In still another aspect of the present invention, a composition comprises the conjugate with a pharmaceutically acceptable 15 carrier.

Another aspect of the present invention is a substantially purified protein having at least about 50% match with best alignment with the amino acid sequences of at least one of the putative homologous proteins of *Streptococcus pyogenes* (SEQ. ID NO. 4), *Actinomyces* 20 *naeslundii* (SEQ. ID NO. 5), *Enterococcus faecalis* (SEQ. ID NO. 6), *Streptococcus mutans* (SEQ. ID. NO. 7) or *Bacillus subtilis* (SEQ. ID NO. 8) or *Streptococcus pneumoniae* (SEQ ID NO. ____) and having sortase-transamidase activity. Preferably, the match is at least about 60% in best alignment; more preferably, the match is at least about 70% in best alignment.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and accompanying drawings where:

Figure 1 is a diagram of the activity of the sortase-transamidase enzyme of the present invention.

Figure 2:

(A) is a diagrammatic representation of the primary structure of the surface protein precursor SEB-SPA490-524.

(B) depicts an SDS-PAGE gel of immunoprecipitated [³⁵S] SEB-SPA490-52 P1 precursor, P2 precursor and mature protein. SM317 and SM329 are two ts mutants that accumulate P2 as compared to wild-type staphylococci (WT).

(C) depicts an SDS-PAGE gel of immunoprecipitated [³⁵S] SEB-SPA490-52 P1 precursor, P2 precursor and mature protein in SM317, SM329 and WT staphylococci following a pulse-chase analysis of SEB-SPA490-524 anchoring.

(D) depicts Staphylococcal strains OS2 (WT), SM317 and SM329 streaked on tryptic soy agar and grown at 42°C.

Figure 3:

(A) is a diagrammatic representation of the primary structure of SEB-MH₆-CWS and its linkage to the cell wall.

(B) depicts a mass spectroscopy profile (MALDI-MS) of solubilized and affinity purified SEB-MH₆-CWS.

(C) depicts a mass spectroscopy profile (MALDI-MS) of solubilized, mutanolysin-released anchor peptides were digested with fl1 hydrolase.

Figure 4:

(A) depicts an SDS-PAGE gel of immunoprecipitated [³⁵S] SEB-SPA490-52 P1 precursor, P2 precursor and mature protein in SM317, SM329 and WT staphylococci transformed with or without pGL1834 (plasmid containing the *srtA* gene cloned into pC194-mcs) following a pulse-chase analysis of SEB-SPA490-524 anchoring.

(B) depicts an SDS-PAGE gel of immunoprecipitated [³⁵S] SEB-SPA490-52 P1 precursor, P2 precursor and mature protein from SM317 transformed with the DNA of either the mutant SM317 (pGL1898) or wild-type strain OS2 (pGL1897).

(C) depicts an SDS-PAGE gel of immunoprecipitated [³⁵S] SEB-SPA490-52 P1 precursor, P2 precursor and mature protein from *S. aureus* OS2 (wild type), SM317 and SM329 transformed with pGL1834 and subjected to pulse-chase analysis.

Figure 5 depicts the size of DNA fragments and the position of the coding region

of the *srtA* gene of *S. aureus* (SEQ ID NO: 2) sufficient for an increase in surface protein anchoring. The concentration of P2 precursor in plasmid transformants of the mutant SM317 was measured by labeling with [³⁵S]methionine and is indicated in percent.

Figure 6 depicts the DNA sequence of the *srtA* gene (SEQ ID NO: 2) and deduced primary structure of the SrtA protein (SEQ ID NO: 3). The NH₂-terminal hydrophobic membrane anchor sequence is boxed. A single cysteine predicted to be the active site for cleavage of cell wall sorting signals at the LPXTG motif is shaded.

Figure 7 depicts a sequence alignment comparing the predicted primary structure of the SrtA protein (Sortase) with that of homologous sequences identified by database searches. Note the conservation of a single cysteine residue as well as its surrounding sequence.

5

Figure 8:

(A) depicts the structure of Seb-Spa490-524 harboring an NH₂-terminal leader (signal) peptide with signal peptidase cleavage site as well as a COOH-terminally fused cell wall sorting signal consisting of the LPXTG motif, hydrophobic domain (*black box*), and positively charged tail (*boxed +*).

10

(B) depicts the SDS-PAGE gel analysis of pulse chase experiment where staphylococcal cultures were labeled with [³⁵S]methionine for 1 min and quenching all further incorporation by the addition of excess unlabeled methionine (chase). P1 precursor, P2 precursor and mature Seb-Spa490-524 were evaluated.

15

Figure 9:

(A) depicts a growth curve for staphylococcal growth with antibiotics added (1, open squares: mock treated; 2, open diamonds: penicillin 10 µg/ml; 3, closed diamonds: moenomycin, 10 µg/ml; 4, closed squares: vancomycin 10 µg/ml).

20

(B) depicts a curve measuring the rate of cell wall sorting in the presence of antibiotics or mock treated as described in (A).

25

Figure 10:

(A) depicts the structure of Seb-Cws-BlaZ harboring an NH₂-terminal signal (leader) peptide and the sorting signal of protein A which consists of an LPXTG motif, hydrophobic (*shaded box*) and charged domains (*boxed RRREL*). The sorting signal is fused to the COOH-terminus of Seb and to the NH₂-terminus of mature BlaZ. Cleavage at the LPXTG motif produces two fragments, an NH₂-terminal cell wall anchored surface protein (Seb) and a COOH-terminal BlaZ domain that is located in the bacterial cytoplasm.

(B) depicts an SDS-PAGE gel analysis of *S. aureus* OS2 (pSeb-Cws-BlaZ) and *S. aureus* OS2 (pSeb-CwsDLPXTG-BlaZ) cell wall sorting. The arrows point to Seb species that were observed in protoplasts but not in whole cells.

Figure 11 depicts a model for the transpeptidation reaction catalyzed by staphylococcal sortase.

Figure 12:

(A) depicts an SDS-PAGE gel analysis of a pulse chance analysis of surface protein anchoring to the cell wall in the presence or absence of release of proteins fro the surface by hydroxylamine.

(B) depicts an SDS-PAGE gel analysis of a pulse chance analysis of surface protein anchoring to the cell wall in the presence or absence of release of proteins fro the surface by hydroxylamine added either 5 min prior to labeling (prior), during pulse-labeling (pulse) or 5 min after quenching to *S. aureus* OS2 cultures.

(C) depicts a bar graph indicating that increasing amounts of hydroxylamine added 5 min prior to labeling of *S. aureus* OS2 cultures caused increasing amounts of surface protein to be released.

Figure 13:

- (A) depicts a Coomassie-stained SDS-PAGE gel used to characterize surface proteins released by hydroxylamine treatment.
- (B) depicts an rpHPLC chromatogram of COOH-terminal anchor peptides released from *S. aureus* BB270 cells via treatment with 0.1 M NH₂OH.
- (C) depicts an rpHPLC chromatogram of COOH-terminal anchor peptides released from *S. aureus* BB270 cells via treatment with 0.1 M NH₂OH.

Figure 14:

- (A) is a bar graph depicting the effect of incubating staphylococcal extracts with the sorting substrate DABCYL-QALPETGEE-EDANS; peptide cleavage is indicated as an increase in fluorescence. The addition of 0.2 M NH₂OH increased peptide cleavage, whereas peptide cleavage was inhibited by the addition of methanethiosulfonate (MTSET), a known inhibitor of sortase.
- (B) depicts an SDS-PAGE gel analysis of *E. coli* XL-1Blue (pHTT5) expressing SrtA_{DN}, in which the NH₂-terminal membrane anchor of sortase (SrtA) has been replaced with a six histidine tag. Lane 1 contains uninduced culture; 2, 1 mM IPTG induced culture; 3, French press extract; 4, the supernatant of centrifuged French press extracts; 5, the sediment of French press extracts; 6, flow-through of affinity chromatography on Ni-NTA; 7, column wash; 8-10, 1 ml fractions eluted with 0.5 M imidazol.

(C) is a bar graph depicting the effect of incubating purified SrtADN with the peptide substrate DABCYL-QALPETGEE-EDANS and cleavage monitored as an increase in fluorescence. The reaction was inhibited by the addition of methanethiosulfonate (MTSET) or organic mercurial (pHMB), while the addition of 0.2 M NH₂OH accelerated cleavage. MTSET-treated SrtADN could be rescued by incubation with 10 mM DTT.

5

DEFINITIONS

As used herein, the terms defined below have the following meanings unless otherwise indicated:

“Nucleic Acid Sequence”: the term “nucleic acid sequence” includes both DNA and RNA unless otherwise specified, and, unless otherwise specified, includes both double-stranded and single-stranded nucleic acids. Also included are hybrids such as DNA-RNA hybrids. In particular, a reference to DNA includes RNA that has either the equivalent base sequence except for the substitution of uracil and RNA for thymine in DNA, or has a complementary base sequence except for the substitution of uracil for thymine, complementarity being determined according to the Watson-Crick base pairing rules. Reference to nucleic acid sequences can also include modified bases as long as the modifications do not significantly interfere either with binding of a ligand such as a protein by the nucleic acid or with Watson-Crick base pairing.

“Mismatch”: as used herein the term “mismatch” includes all unpaired bases when two nucleic acid sequences are hybridized with best alignment in the context of nucleic acid hybridization. In other words, the term “mismatch” includes not only situations in which the same number of bases are present in the two sequences or segments of sequences, but in which some bases do not form Watson-Crick pairs because of their sequences, but also situations in which different numbers of bases are present in the two sequences because of insertions or deletions, referred to generically as “indels.” In this latter situation, certain of the bases in the longer sequence must be unpaired and may loop out from the hybrid.

“Match”: as used herein the term “match” includes all paired amino acids when two amino acid sequences are compared with best alignment in the context in terms of protein sequence comparison. Amino acid “sequence identity” percentages include only identical amino acid pairing when amino acid sequences are matched in best alignment. Amino acid “sequence similarity” percentages include both similar and identical amino acids when amino acid sequences are matched in best alignment. Similar amino acids are amino acids which share similar physical and/or chemical properties. The following is a listing of amino acids which are

considered to be similar, or conservative amino acids relative to one another, as substitutions of each of these amino acids for the other in a sequence often do not disrupt the structure or function of the molecule as the amino acids share similar physical and/or chemical properties. In particular, the conservative amino acid substitutions can be any of the following: (1) any of
5 isoleucine for leucine or valine, leucine for isoleucine, and valine for leucine or isoleucine; (2) aspartic acid for glutamic acid and glutamic acid for aspartic acid; (3) glutamine for asparagine and asparagine for glutamine; and (4) serine for threonine and threonine for serine.

Other substitutions can also be considered conservative, depending upon the environment of the particular amino acid. For example, glycine (G) and alanine (A) can
10 frequently be interchangeable, as can be alanine and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the different pK's of these two amino acid residues or their different sizes are not significant. Still other changes can
15 be considered "conservative" in particular environments. For example, if an amino acid on the surface of a protein is not involved in a hydrogen bond or salt bridge interaction with another molecule, such as another protein subunit or a ligand bound by the protein, negatively charged amino acids such as glutamic acid and aspartic acid can be substituted for by positively charged amino acids such as lysine or arginine and vice versa. Histidine (H), which is more weakly basic
20 than arginine or lysine, and is partially charged at neutral pH, can sometimes be substituted for these more basic amino acids. Additionally, the amides glutamine (Q) and asparagine (N) can sometimes be substituted for their carboxylic acid homologues, glutamic acid and aspartic acid.

"Antibody": as used herein the term "antibody" includes both intact antibody molecules of the appropriate specificity, and antibody fragments (including Fab, F(ab'), Fv, and
25 F(ab')₂), as well as chemically modified intact antibody molecules and antibody fragments, including hybrid antibodies assembled by in vitro reassociation of subunits. Also included are single-chain antibody molecules generally denoted by the term sFv and humanized antibodies in which some or all of the originally non-human constant regions are replaced with constant

regions originally derived from human antibody sequences. Both polyclonal and monoclonal antibodies are included unless otherwise specified. Additionally included are modified antibodies or antibodies conjugated to labels or other molecules that do not block or alter the binding capacity of the antibody.

5

DESCRIPTION

A substantially purified sortase-transamidase enzyme from Gram-positive bacteria, particularly *Staphylococcus aureus*, has been identified and purified.

The properties of this enzyme make it a logical target for antibiotic action. This enzyme also catalyzes covalent crosslinkage of proteins to the peptidoglycan of Gram-positive bacteria.

10

I. THE SORTASE-TRANSAMIDASE ENZYME

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

One aspect of the invention is a substantially purified sortase-transamidase enzyme from a Gram-positive bacterium. As used herein, the term "substantially purified" means having a specific activity of at least tenfold greater than the sortase-transamidase activity present in a crude extract, lysate, or other state from which proteins have not been removed and also in substantial isolation from proteins found in association with sortase-transamidase in the cell.

15

20

25

The enzyme has a molecular weight of about 23,539 daltons. The enzyme catalyzes a reaction that covalently crosslinks the carboxyl-terminus of a protein having a sorting signal to the peptidoglycan of the Gram-positive bacterium. The sorting signal has: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif. In this sorting signal, X₃ can be any of the twenty naturally-occurring L-amino acids. X₄ can be alanine, serine, or threonine. Preferably, X₄ is threonine.

The sortase-transamidase is believed to occur in all Gram-positive bacteria. In particular, the enzyme exists in *Mycobacterium*, *Nocardia*, *Actinomyces*, *Staphylococcus*, *Streptococcus*, *Listeria*, *Enterococcus*, *Bacillus*, and *Pneumococcus*. Specifically, the enzyme exists in the following species: *Staphylococcus aureus*, *S. sobrinus*, *Enterococcus faecalis*,
5 *Streptococcus pyogenes*, *Bacillus subtilis*, *Streptococcus pneumoniae*, and *Listeria monocytogenes*.

Preferably the enzyme is isolated from *Staphylococcus aureus*, and more preferably is a product of the *srtA* gene of *S. aureus*.

10 A. Amino Acid Sequence

The sortase-transamidase of the present invention includes therein an amino acid sequence of: M-K-K-W-T-N-R-L-M-T-I-A-G-V-V-L-I-L-V-A-A-Y-L-F-A-K-P-H-I-D-N-Y-L-H-D-K-D-K-D-E-K-I-E-Q-Y-D-K-N-V-K-E-Q-A-S-K-D-K-K-Q-Q-A-K-P-Q-I-P-K-D-K-S-K-V-A-G-Y-I-E-I-P-D-A-D-I-K-E-P-V-Y-P-G-P-A-T-P-E-Q-L-N-R-G-V-S-F-A-E-E-N-E-S-L-D-
15 D-Q-N-I-S-I-A-G-H-T-F-I-D-R-P-N-Y-Q-F-T-N-L-K-A-A-K-K-G-S-M-V-Y-F-K-V-G-N-E-T-R-K-Y-K-M-T-S-I-R-D-V-K-P-T-D-V-G-V-L-D-E-Q-K-G-K-D-K-Q-L-T-L-I-T-C-D-D-Y-N-E-K-T-G-V-W-E-K-R-K-I-F-V-A-T-E-V-K (SEQ ID NO: 3).

Also within the scope of the present invention are substantially purified protein molecules that are mutants of the sequence of SEQ ID NO:3 that preserve the sortase-
20 transamidase activity. In particular, the conservative amino acid substitutions can be any of the following: (1) any of isoleucine for leucine or valine, leucine for isoleucine, and valine for leucine or isoleucine; (2) aspartic acid for glutamic acid and glutamic acid for aspartic acid; (3) glutamine for asparagine and asparagine for glutamine; and (4) serine for threonine and threonine for serine.

25 Other substitutions can also be considered conservative, depending upon the environment of the particular amino acid. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can be alanine and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and

sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the different pK's of these two amino acid residues or their different sizes are not significant. Still other changes can be considered "conservative" in particular environments. For example, if an amino acid on the surface of a protein is not involved in a hydrogen bond or salt bridge interaction with another molecule, such as another protein subunit or a ligand bound by the protein, negatively charged amino acids such as glutamic acid and aspartic acid can be substituted for by positively charged amino acids such as lysine or arginine and vice versa. Histidine (H), which is more weakly basic than arginine or lysine, and is partially charged at neutral pH, can sometimes be substituted for these more basic amino acids. Additionally, the amides glutamine (Q) and asparagine (N) can sometimes be substituted for their carboxylic acid homologues, glutamic acid and aspartic acid.

The amino acid sequence (SEQ ID NO: 3) of sortase-transamidase from *Staphylococcus aureus* has substantial homology with sequences of enzymes from other Gram-positive bacteria. There is about a 31% sequence identity (and about 44% sequence similarity) with best alignment over the entire sequenced region of the *S. pyogenes* open reading frame (SEQ. ID NO. 4). There is about a 28% sequence identity (and about 44% sequence similarity) with best alignment over the entire sequenced region of the *A. naeslundii* open reading frame (SEQ. ID NO. 5). There is about a 27% sequence identity (and about 47% sequence similarity) with best alignment over the entire sequenced region of the *S. mutans* open reading frame (SEQ. ID NO. 7). There is about a 25% sequence identity (and about 45% sequence similarity) with best alignment over the entire sequenced region of the *E. faecalis* open reading frame (SEQ. ID NO. 6). There is about a 23% identity and about a 38% similarity between the sequence with best alignment over the entire sequenced region of the *B. subtilis* open reading frame (SEQ. ID NO. 8), as compared with the *S. mutans* open reading frame (SEQ. ID NO. 7), with a lower degree of sequence identity and similarity between the *B. subtilis* and *S. pyogenes* open reading frames. These matches are shown in Figure 7.

Additionally, there is about a 32% sequence identity and about a 47% sequence similarity with best alignment over the entire sequence between the *S. aureus* open reading frame

(SEQ. ID NO. 3) and a protein designated srtA from *Streptococcus pneumoniae* (SEQ. ID NO. 34). The sequence of the srtA protein is

MSRTKLRALLGYLLMLVACLIPIYCFGQMVLQSLGQVKGHATFVKSM TTEMYQEQQN
HSLAYNQRLASQNRIVDPFLAEGYEVNYQVSDDPDAVYGYLSIPSLEIMEPVYLGADYH
5 HLGMGLAHVDGTPLPLDGTGIRSVIAGHRAEPSHVFFRHL DQLKVG DALYYDNGQEIVE
YQMMDTEILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAVYQKSDPQTAA
VARVAFTKEGQSVSRVATSQWL YRGLVVL AFLGILFVLWKLARLLRGK (SEQ ID NO.

34). Similarly, there is about a 30% sequence identity and about a 46% sequence similarity with best alignment over the entire sequence between the *S. aureus* open reading frame (SEQ. ID

10 NO.3) and a protein designated srtB from *Streptococcus pneumoniae* (SEQ. ID NO. 35). The sequence of the srtB protein is

MDNSRRSRKKGT KKKKHPLILLIFLVGFAVAIYPLVSRYYYRISNEVIKEFDET VSQMD
KAELEERWRLAQAFNATLKPSEILDPFTEQEKKKG VSEYANMLKVHERIGYVEIPAIDQE
IPMYVGTSEDILQKGAGLLEGASLPVGGENTHTVIT AHRGLPTAELFSQLDKMKKGDIFY
15 LHVLDQVLAYQVDQIVTVEPNDFEPVLIQHGEDYATLLTCTPYMINSHRLLVRGKRIPYT
APIAERNRAVRERGQFWLWLLLGAMAVILL LLYRVYRNRRIVKGLEKQLEGRHVKD

(SEQ. ID NO. 35). Similarly, there is about a 29% sequence identity and about a 43% sequence similarity with best alignment over the entire sequence between the *S. aureus* open reading frame (SEQ. ID NO.3) and a protein designated srtC from *Streptococcus pneumoniae* (SEQ ID NO.

20 36). The sequence of the srtC protein is

MDNSRRSRKKGT KKKKHPLILLIFLVGFAVAIYPLVSRYYYRISNEVIKEFDET VSQMD
KAELEERWRLAQAFNATLKPSEILDPFTEQEKKKG VSEYANMLKVHERIGYVEIPAIDQE
IPMYVGTSEDILQKGAGLLEGASLPVGGENTHTVIT AHRGLPTAELFSQLDKMKKGDIFY
LHVLDQVLAYQVDQIVTVEPNDFEPVLIQHGEDYATLLTCTPYMINSHRLLVRGKRIPYT
25 APIAERNRAVRERGQFWLWLLLGAMAVILL LLYRVYRNRRIVKGLEKQLEGRHVKD

(SEQ ID NO. 36).

Therefore, another aspect of the present invention is a substantially purified protein molecule that has at least a 18% sequence identity match, preferably a 20% sequence

identity match, and most preferably a 30% sequence identity match with best alignment with the *S. pyogenes*, *A. naeslundii*, *S. mutans*, *E. faecalis* or *B. subtilis* open reading frame of Figure 7 and that has sortase-transamidase activity. Further, another aspect of the present invention is a substantially purified protein molecule that has at least a 30% sequence similarity match, preferably a 40% sequence similarity match, and most preferably a 50% sequence similarity match with best alignment with the *S. pyogenes*, *A. naeslundii*, *S. mutans*, *E. faecalis* or *B. subtilis* open reading frame of Figure 7 and that has sortase-transamidase activity.

The sortase-transamidase is a cysteine protease.

B. Activity of the Sortase-Transamidase

The activity of the sortase-transamidase enzyme of the present invention is shown, in general, in Figure 1. The enzyme first cleaves a polypeptide having a sorting signal within the LPX₃X₄G motif. Cleavage occurs after residue X₄, normally a threonine; as indicated above, this residue can also be a serine or alanine residue. This residue forms a covalent intermediate with the sortase. The next step is the transamidation reaction that transfers the cleaved carboxyl terminus of the protein to be sorted to the -NH₂ of the pentaglycine crossbridge within the peptidoglycan precursor. The peptidoglycan precursor is then incorporated into the cell wall by a transglycosylase reaction with the release of undecaprenyl phosphate. The mature anchored polypeptide chains are thus linked to the pentaglycine cross bridge in the cell wall which is tethered to the ε-amino side chain of an unsubstituted cell wall tetrapeptide. A carboxypeptidase may cleave a D-Ala-D-Ala bond of the pentapeptide structure to yield the final branched anchor peptide in the staphylococcal cell wall.

The sorting signal has: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region.

In the motif, X₃ can be any of the 20 naturally-occurring L-amino acids. X₄ can be any of threonine, serine, or alanine. Preferably, X₄ is threonine (O. Schneewind et al., "Cell

Wall Sorting Signals in Surface Proteins of Gram-Positive Bacteria," EMBO J. 12:4803-4811 (1993)).

Preferably, the substantially hydrophobic domain carboxyl to the motif includes no more than about 7 charged residues or residues with polar side chains. For the purposes of this specification, these residues include the following: aspartic acid, glutamic acid, lysine, and arginine as charged residues, and serine, threonine, glutamine, and asparagine as polar but uncharged residues. Preferably, the sequence includes no more than three charged residues.

Representative sequences suitable for sorting signals for use with the sortase-transamidase of the present invention include, but are not limited to the following: E-E-N-P-F-I-G-T-T-V-F-G-G-L-S-L-A-L-G-A-A-L-L-A-G (SEQ ID NO: 9), the hydrophobic domain of the staphylococcal proteinase (SPA) sorting signal from *Staphylococcus aureus*; (2) G-E-E-S-T-N-K-G-M-L-F-G-G-L-F-S-I-L-G-L-A-L-L (SEQ ID NO:10), the SNBP signal of *S. aureus*; (3) D-S-S-N-A-Y-L-P-L-L-G-L-V-S-L-T-A-G-F-S-L-L-G-L (SEQ ID NO: 11), the SPAA signal of *S. sobrinus*, (4) E-K-Q-N-V-L-L-T-V-V-G-S-L-A-A-M-L-G-L-A-G-L-G-F (SEQ ID NO:12), the PRGB signal of *Enterococcus faecalis*, (5) S-I-G-T-Y-L-F-K-I-G-S-A-A-M-I-G-A-I-G-I-Y-I-V (SEQ ID NO:13), the TEE signal of *Streptococcus pyogenes*, and (6) D-S-D-N-A-L-Y-L-L-L-G-L-L-A-V-G-T-A-M-A-L-T (SEQ ID NO:14), the INLA signal of *Listeria monocytogenes*. Other hydrophobic domains can be used as part of the sorting signal.

The third portion of the sorting signal is a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain. At least one of the two positively charged residues is arginine. The charged tail can also contain other charged amino acids, such as lysine. Preferably, the charged tail region includes two or more arginine residues. The two positively charged residues are located at residues 31-33 from the motif. Preferably, the two arginine residues are either in succession or are separated by no more than one intervening amino acid. Preferably, the charged tail is at least five amino acids long, although four is possible. Among the charged tails that can be used are the following: (1) R-R-R-E-L (SEQ ID NO:15), from the SPA signal of *S. aureus*; (2) R-R-N-K-K-N-H-K-A (SEQ ID NO:16), from the SNBP signal of *S. aureus*; (3) R-R-K-Q-D (SEQ ID NO:17), from the SPAA

signal of *S. sobrinus*; (4) K-R-R-K-E-T-K (SEQ ID NO:18), from the PRGB signal of *E. faecalis*; (5) K-R-R-K-A (SEQ ID NO:19), from the TEE signal of *S. pyogenes*; (6), K-R-R-H-V-A-K-H (SEQ ID NO:20), from the FIM sorting signal of *Actinomyces viscosus*, and (7) K-R-R-K-S (SEQ ID NO:21), from the BAC sorting signal of *Streptococcus agalactiae*; (8) K-R-K-E-E-N (SEQ ID NO:22), from the EMM signal of *Streptococcus pyogenes*.

Also usable as the charged tail portion of the sorting signal are the following sequences produced by mutagenesis from the SPA signal of *S. aureus*. These include R-R-R-E-S (SEQ ID NO: 23), R-R-R-S-L (SEQ ID NO: 24), R-R-S-E-L (SEQ ID NO: 25), R-S-R-E-L (SEQ ID NO: 26) and S-R-R-E-L (SEQ ID NO: 27). Other charged tails that are usable as part of the sorting signal can be derived from a polyserine tail, itself inactive, by replacement of one or more of the serine residues with the basic amino acid arginine. These include R-R-S-S-S (SEQ ID NO: 28), R-S-R-S-S (SEQ ID NO:29), and S-R-R-S-S (SEQ ID NO:30). Other sorting signals can also be used.

II. THE GENE ENCODING THE SORTASE-TRANSAMIDASE ENZYME

A. Isolation of the Sortase-Transamidase Enzyme Gene

The gene for the sortase-transamidase enzyme in *Staphylococcus aureus*, the *srtA* gene, has been isolated. The isolation process is described in detail in the Example below; in general, this process comprises: (1) the generation of temperature-sensitive mutants through chemical mutagenesis, such as with the DNA modifying agent N-methyl-N-nitro-N-nitrosoguanidine; (2) screening for temperature-sensitive mutants; (3) screening the temperature-sensitive mutants for a block in protein sorting by the use of a construct harboring the staphylococcal enterotoxin B (SEB) gene fused to the cell wall sorting signal of staphylococcal Protein A (SPA), to locate mutants that accumulate a precursor molecule formed by cleavage of an amino-terminal signal peptide but that is not then processed by cleavage of the carboxyl-terminal sorting signal; (4) generation of a *S. aureus* chromosomal library and complementation of the sorting defect leading to abnormal accumulation of the P2 precursor; and (5) sequencing and characterization of the *S. aureus* complementing determinants.

B. Sequence of the Sortase-Transamidase Gene

The above procedure yielded the entire coding sequence for the sortase-transamidase gene, *srtA*. This sequence is:

5 ATGAAAAAATGGACAAATCGATTAATGACAATCGCTGGTGTGGTACTTATCCTAGTG
GCAGCATATTTGTTTGCTAAACCACATATCGATAATTATCTTCACGATAAAGATAAA
GATGAAAAGATTGAACAATATGATAAAAATGTAAAAGAACAGGCGAGTAAAGATA
AAAAGCAGCAAGCTAAACCTCAAATTCCGAAAGATAAATCGAAAGTGGCAGGCTAT
ATTGAAATTCCAGATGCTGATATTAAGAACCAGTATATCCAGGACCAGCAACACCT
10 GAACAATTAAATAGAGGTGTAAGCTTTGCAGAAGAAAATGAATCACTAGATGATCA
AAATATTTCAATTGCAGGACACACTTTCATTGACCGTCCGAAGTATCAATTTACAAA
TCTTAAAGCAGCCAAAAAAGGTAGTATGGTGTACTTTAAAGTTGGTAATGAAACAC
GTAAGTATAAAATGACAAGTATAAGAGATGTAAAGCCTACAGATGTAGGAGTTCTA
GATGAACAAAAAGGTAAAGATAAACAATTAACATTAATTACTTGTGATGATTACAA
15 TGAAAAGACAGGCGTTTGGGAAAAACGTAAAATCTTTGTAGCTACAGAAGTCAAAT
AA (SEQ ID NO: 2). The last three nucleotides, TAA, of this sequence are the stop codon.

Accordingly, within the scope of the present invention is a nucleic acid sequence encoding a substantially purified sortase-transamidase enzyme from a Gram-positive bacterium. The enzyme encoded has a molecular weight of about 23,539 daltons and catalyzes a reaction
20 that covalently cross-links the carboxyl-terminus of a protein having the sorting signal described above to the peptidoglycan of a gram-positive bacterium. The nucleic acid sequence includes therein the sequence of SEQ ID NO: 2 or a sequence complementary to SEQ ID NO: 2.

Also included within the present invention is a nucleic acid sequence encoding a substantially purified sortase-transamidase enzyme from a Gram-positive bacterium with a
25 molecular weight of about 23,539 daltons, where the enzyme catalyzes the cross-linking reaction where the nucleic acid sequence hybridizes with at least one of: (1) the sequence of SEQ ID NO: 2; (2) a sequence complementary to SEQ ID NO: 2; or (3) a sequence complementary to SEQ ID NO: 2 with no greater than about a 15% mismatch under stringent conditions. Preferably, the

degree of mismatch is no greater than about 5%; most preferably the mismatch is no greater than about 2%.

Also within the present invention is a nucleic acid sequence encoding a substantially purified sortase-transamidase enzyme from a Gram-positive bacterium with a molecular weight of about 23,539 daltons and catalyzes the cross-linking reaction described above involving the sorting signal, where the enzyme includes therein an amino acid sequence selected from the group consisting of: (1) M-K-K-W-T-N-R-L-M-T-I-A-G-V-V-L-I-L-V-A-A-Y-L-F-A-K-P-H-I-D-N-Y-L-H-D-K-D-K-D-E-K-I-E-Q-Y-D-K-N-V-K-E-Q-A-S-K-D-K-K-Q-Q-A-K-P-Q-I-P-K-D-K-S-K-V-A-G-Y-I-E-I-P-D-A-D-I-K-E-P-V-Y-P-G-P-A-T-P-E-Q-L-N-R-G-V-S-F-A-E-E-N-E-S-L-D-D-Q-N-I-S-I-A-G-H-T-F-I-D-R-P-N-Y-Q-F-T-N-L-K-A-A-K-K-G-S-M-V-Y-F-K-V-G-N-E-T-R-K-Y-K-M-T-S-I-R-D-V-K-P-T-D-V-G-V-L-D-E-Q-K-G-K-D-K-Q-L-T-L-I-T-C-D-D-Y-N-E-K-T-G-V-W-E-K-R-K-I-F-V-A-T-E-V-K (SEQ ID NO: 3); and (2) sequences incorporating one or more conservative amino acid substitutions in SEQ ID NO:3 wherein the conservative amino acid substitutions are any of the following: (1) any of isoleucine, leucine and valine for any other of these amino acids; (2) aspartic acid for glutamic acid and vice versa; (3) glutamine for asparagine and vice versa; and (4) serine for threonine and vice versa. Alternative nucleic acid sequences can be determined using the standard genetic code; the alternative codons are readily determinable for each amino acid in this sequence.

Construction of nucleic acid sequences according to the present invention can be accomplished by techniques well known in the art, including solid-phase nucleotide synthesis, the polymerase chain reaction (PCR) technique, reverse transcription of DNA from RNA, the use of DNA polymerases and ligases, and other techniques. If an amino acid sequence is known, the corresponding nucleic acid sequence can be constructed according to the genetic code.

C. Vectors and Host Cells Transformed with Vectors

Another aspect of the invention is a vector comprising a nucleic acid sequence according to the present invention operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence. Such control sequences are

well known in the art and include operators, promoters, enhancers, promoter-proximal elements and replication origins. The techniques of vector construction, including cloning, ligation, gap-filling, the use of the polymerase chain reaction (PCR) procedure, solid-state oligonucleotide synthesis, and other techniques, are all well known in the art and need not be described further here.

Another aspect of the present invention is a host cell transfected with a vector according to the present invention. Among the host cells that can be used are gram-positive bacteria such as *Staphylococcus aureus*.

Transfection, also known as transformation, is done using standard techniques appropriate to the host cell used, particularly *Staphylococcus aureus*. Such techniques are described, for example, in R.P. Novick, "Genetic Systems in Staphylococci," Meth. Enzymol. 204: 587-636 (1991), as well as in O. Schneewind et al., "Sorting of Protein A to the Staphylococcal Cell Wall," Cell 70: 267-281 (1992).

III. SORTASE-TRANSAMIDASE AS A TARGET FOR ANTIBIOTIC ACTION

A. A Site for Antibiotic Action

The reaction carried out by the sortase-transamidase of the present invention presents a possible target for a new class of antibiotics to combat medically relevant infections caused by numerous gram-positive organisms. Because this is a novel site of antibiotic action, these antibiotics have the advantage that resistance by the bacterium has not had a chance to develop.

Such antibiotics can include compounds with structures that mimic the cleavage site, such as compounds with a structure similar to methyl methanethiosulfonate or, more generally, alkyl methanethiosulfonates. The sortase-transamidase of the present invention is believed to be a cysteine protease. Other antibiotics that may inhibit the activity of the sortase-transamidase in the present invention include inhibitors that would be specific for cysteine-modification in a β -lactam framework. These inhibitors can, but need not necessarily, have active moieties that would form mixed disulfides with the cysteine sulfhydryl. These active

moieties could be derivatives of methanethiosulfonate, such as methanethiosulfonate ethylammonium, methanethiosulfonate ethyltrimethylammonium, or methanethiosulfonate ethylsulfonate (J.A. Javitch et al., "Mapping the Binding Site Crevice of the Dopamine D2 Receptor by the Substituted-Cysteine Accessibility Method," Neuron, 14: 825-831 (1995); M.H. Akabas & A. Karlin, "Identification of Acetylcholine Receptor Channel-Lining Residues in the M1 Segment of the α -Subunit," Biochemistry 34: 12496-12500 (1995)). Similar reagents, such as alkyl alkanethiosulfonates, i.e., methyl methanethiosulfonate, or alkoxycarbonylalkyl disulfides, have been described (D.J. Smith et al., "Simple Alkanethiol Groups for Temporary Blocking of Sulfhydryl Groups of Enzymes," Biochemistry 14: 766-771 (1975); W.N. Valentine & D.E. Paglia, "Effect of Chemical Modification of Sulfhydryl Groups of Human Erythrocyte Enzymes," Am. J. Hematol. 11: 111-124 (1981)). Other useful inhibitors involve derivatives of 2-trifluoroacetylaminobenzene sulfonyl fluoride (J.C. Powers, "Proteolytic Enzymes and Their Active-Site-Specific Inhibitors: Role in the Treatment of Disease," in Modification of Proteins), in a β -lactam framework, peptidyl aldehydes and nitriles (E. Dufour et al., "Peptide Aldehydes and Nitriles as Transition State Analog Inhibitors of Cysteine Proteases," Biochemistry 34: 9136-9143 (1995); J. O. Westerik & R. Wolfenden, "Aldehydes as Inhibitors of Papain," J. Biol. Chem. 247: 8195-8197 (1972)), peptidyl diazomethyl ketones (L. Björck et al., "Bacterial Growth Blocked by a Synthetic Peptide Based on the Structure of a Human Proteinase Inhibitor," Nature 337: 385-386 (1989)), peptidyl phosphoramidates (P.A. Bartlett & C.K. Marlowe, "Phosphoramidates as Transition-State Analogue Inhibitors of Thermolysin," Biochemistry 22: 4618-4624 (1983)), phosphonate monoesters such as derivatives or analogues of *m*-carboxyphenyl phenylacetamidomethylphosphonate (R.F. Pratt, "Inhibition of a Class C β -Lactamase by a Specific Phosphonate Monoester," Science 246: 917-919 (1989)), maleimides and their derivatives, including derivatives of such bifunctional maleimides as *o*-phenylenebismaleimide, *p*-phenylenebismaleimide, *m*-phenylenebismaleimide, 2,3-naphthalenebismaleimide, 1,5-naphthalenebismaleimide, and azophenylobismaleimide, as well as monofunctional maleimides and their derivatives (J.V. Moroney et al., "The Distance Between Thiol Groups in the γ Subunit of Coupling Factor 1 Influences the Proton Permeability of

Thylakoid Membranes," J. Bioenerget. Biomembr. 14: 347-359 (1982)), peptidyl halomethyl ketones (chloromethyl or fluoromethyl ketones), peptidyl sulfonium salts, peptidyl acyloxymethyl ketones, derivatives and analogues of epoxides, such as E-64 (N-[N-(L-trans-carboxyoxiran-2-carbonyl)-L-leucylagmatine), E-64c (a derivative of E-64 in which the agmatine moiety is replaced by an isoamylamine moiety), E-64c ethyl ester, Ep-459 (an analogue of E-64 in which the agmatine moiety is replaced by a 1,4-diaminopropyl moiety), Ep-479 (an analogue of E-64 in which the agmatine moiety is replaced by a 1,7-diheptylamino moiety), Ep-460 (a derivative of Ep-459 in which the terminal amino group is substituted with a Z (benzyloxycarbonyl) group), Ep-174 (a derivative of E-64 in which the agmatine moiety is removed, so that the molecule has a free carboxyl residue from the leucine moiety), Ep-475 (an analogue of E-64 in which the agmatine moiety is replaced with a $\text{NH}_2\text{-(CH}_2\text{)}_2\text{-CH-(CH}_3\text{)}_2$ moiety), or Ep-420 (a derivative of E-64 in which the hydroxyl group is benzoylated, forming an ester, and the leucylagmatine moiety is replaced with isoleucyl-O-methyltyrosine), or peptidyl O-acyl hydroxamates (E Shaw, "CysteinyI Proteases and Their Selective Inactivation), pp 271-347). Other inhibitors are known in the art.

Modification of other residues may also result in inhibition of the enzyme.

B. Screening Methods

Another aspect of the present invention is a method for screening a compound for anti-sortase-transamidase activity. This is an important aspect of the present invention, because it provides a method for screening for compounds that disrupt the sorting process and thus have potential antibiotic activity against Gram-positive bacteria.

In general, this method comprises the steps of: (1) providing an active fraction of sortase-transamidase enzyme; (2) performing an assay for sortase-transamidase activity in the presence and in the absence of the compound being screened; and (3) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound.

The active fraction of sortase-transamidase enzyme can be a substantially purified sortase-transamidase enzyme preparation according to the present invention, but can be a less purified preparation, such as a partially purified particulate preparation as described below.

The enzymatic activity can be measured by the cleavage of a suitable substrate, such as the construct having the Staphylococcal Enterotoxin B (SEB) gene fused to the cell wall sorting signal of Staphylococcal Protein A (SPA). The cleavage can be determined by monitoring the molecular weight of the products by sodium dodecyl sulfate-polyacrylamide gel electrophoresis or by other methods.

One particularly preferred assay for sortase-transamidase activity is the following:

Staphylococcal soluble RNA (sRNA) is prepared from *S. aureus* by a modification of the technique of Zubay (G. Zubay, J. Mol. Biol. 4: 347-356 (1962)). An overnight culture of *S. aureus* is diluted 1:10 in TSB and incubated at 37°C for 3 hr. The cells are harvested by centrifugation at 6000 rpm for 15 min.

For every gram of wet cell pellets, 2 ml of 0.01 M magnesium acetate, 0.001 M Tris, pH 7.5 is used to suspend the pellets. The cell pellets are beaten by glass bead beater for 45 minutes in 5 minute intervals. The suspension is centrifuged twice at 2500 rpm for 5 minutes to remove the glass beads, then 0.5 ml phenol is added to the suspension. The suspension is vigorously shaken for 90 minutes at 4°C, and then centrifuged at 18,000 x g for 15 minutes. The nucleic acids in the top layer are precipitated by addition of 0.1 volume of 20% potassium acetate and 2 volumes of ethanol, then stored at 4°C for at least 36 hours. The precipitate is obtained by centrifugation at 5,000 x g for 5 minutes. Cold NaCl (1 ml) is added to the precipitate and stirred at 4°C for 1 hour. The suspension is centrifuged at 15,000 x g for 30 minutes. The sediments are washed with 0.5 ml of cold 1 M NaCl. The supernatants are combined and 2 volumes of ethanol is added to precipitate the tRNA. The precipitate is suspended in 0.1 ml of 0.2 M glycine, pH 10.3 and incubated for 3 hr at 37°C. This suspension is then made 0.4 M in NaCl and the RNA is precipitated by addition of 2 volumes of ethanol. The precipitate is dissolved in 0.7 ml of 0.3 M sodium acetate, pH 7.0. To this is slowly added 0.5 volume of isopropyl alcohol, with stirring. The precipitate is removed by centrifugation at 8,000 x g for 5 min. This precipitate is

redissolved in 0.35 ml of 0.3 M sodium acetate, pH 7.0. To this is added 0.5 volume of isopropyl alcohol, using the same procedure as above. The precipitate is also removed by centrifugation. The combined supernatants from the two centrifugations are treated further with 0.37 ml of isopropyl alcohol. The resulting precipitate is dissolved in 75 μ l of water and dialyzed against water overnight at 4°C. This sRNA is used in the sortase-transamidase assay.

Particulate sortase-transamidase enzyme is prepared for use in the assay by a modification of the procedure of Chatterjee & Park (A.N. Chatterjee & J.T. Park, Proc. Natl. Acad. Sci. USA 51: 9-16 (1964)). An overnight culture of *S. aureus* OS2 is diluted 1:50 in TSB and incubated at 37°C for 3 hr. Cells are harvested by centrifugation at 6000 rpm for 15 minutes, and washed twice with ice-cold water. The cells are disrupted by shaking 7 ml of 1 3% suspension of cells in 0.05 M Tris-HCl buffer, pH 7.5, 0.1 mM MgCl₂, and 1 mM 2-mercaptoethanol with an equal volume of glass beads for 10-15 minutes in a beater. The glass beads are removed by centrifugation at 2000 rpm for 5 minutes. The crude extract is then centrifuged at 15,000 x g for 5 minutes. The supernatant is centrifuged again at 100,000 x g for 30 minutes. The light yellow translucent pellet is resuspended in 2 to 4 ml of 0.02 M Tris-HCl buffer, pH 7.5, containing 0.1 mM MgCl₂ and 1 mM 2-mercaptoethanol. This suspension represents the crude particulate enzyme and is used in the reaction mixture below.

The supernatant from centrifugation at 100,000 x g is passed through gel filtration using a Sephadex® G-25 agarose column (Pharmacia) to remove endogenous substrates. This supernatant is also used in the reaction mixture.

The complete reaction mixture contains in a final volume of 30 μ l (M. Matsushashi et al., Proc. Natl. Acad. Sci. USA 54: 587-594 (1965)): 3 μ mol of Tris-HCl, pH 7.8; 0.1 μ mol of MgCl₂; 1.3 μ mol of KCl; 2.7 nmol of [³H] glycine (200 μ Ci/ μ mol); 2 nmol of UDP-M-pentapeptide; 5 nmol of UDP-N-acetylglucosamine; 0.2 μ mol of ATP; 0.05 μ mol of potassium phosphoenolpyruvate; 2.05 μ g of chloramphenicol; 5 μ g of pyruvate kinase; 0.025 μ mol of 2-mercaptoethanol; 50 μ g of staphylococcal sRNA prepared as above; 4 μ g (as protein) of supernatant as prepared above; 271 μ g of particulate enzyme prepared as above; and 8 nmol of a synthesized soluble peptide (HHHHHHAQALEPTGEENPF) (SEQ ID NO: 32) as a substrate.

The mixture is incubated at 20°C for 60 minutes. The mixture is then heated at 100°C for 1 minute. The mixture is diluted to 1 ml and precipitated with 50 µl nickel resin, and washed with wash buffer (1% Triton X-100, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 7.5). The nickel resin beads are counted in a scintillation counter to determine ³H bound to the beads.

5 The effectiveness of the compound being screened to inhibit the activity of the sortase-transamidase enzyme can be determined by adding it to the assay mixture in a predetermined concentration and determining the resulting degree of inhibition of enzyme activity that results. Typically, a dose-response curve is generated using a range of concentrations of the compound being screened.

10 The particulate enzyme preparation of sortase-transamidase employed in this protocol can be replaced with any other sortase-transamidase preparation, purified or crude, staphylococcal, recombinant, or from any other source from any other Gram-positive bacterium as described above.

15 The soluble peptide is captured in this embodiment by its affinity for nickel resin as a result of the six histidine residues. More than six histidine residues can be used in the peptide. As an alternative, the soluble peptide can be captured by an affinity resulting from other interactions, such as streptavidin-biotin, glutathione S-transferase-glutathione, maltose binding protein-amylose, and the like, by replacing the six histidine residues with the amino acid sequence that constitutes the binding site in the peptide and employing the appropriate solid
20 phase affinity resin containing the binding partner. Suitable peptides can be prepared by solid phase peptide synthesis using techniques well known in the art, such as those described in M. Bodanszky, "Peptide Chemistry: A Practical Textbook" (2d ed., Springer-Verlag, Berlin, 1993). For example, if the glutathione S-transferase-glutathione interaction is used, the active site of glutathione S-transferase (D.B. Smith & K.S. Johnson, "Single-Step Purification of Polypeptides
25 Expressed in *Escherichia coli* as Fusions with Glutathione S-Transferase," Gene 67: 31-40 (1988)) can be substituted for the six histidine residues, and glutathione can be bound to the solid support.

Express Mail # EL270921369US

Alternatively, the soluble peptide can be released from the sortase by hydroxylaminolysis and then quantitated or monitored. The strong nucleophile hydroxylamine attacks thioester to form hydroxamate with carboxyl, thereby regenerating the enzyme sulfhydryl. Hydroxylaminolysis can be carried out in 50 mM Tris-HCl, pH 7.0 with a
5 concentration of 0.1 M hydroxylamine for 60 minutes. The released peptide, for example, can be quantitated by mass spectroscopy or other methods.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211

IV. USE OF SORTASE-TRANSAMIDASE FOR PROTEIN AND PEPTIDE DISPLAY

A. Methods for Protein and Peptide Display

The sortase-transamidase enzyme of the present invention can also be used in a method of displaying a polypeptide on the surface of a gram-positive bacterium.

5 In general, a first embodiment of this method comprises the steps of: (1) expressing a polypeptide having a sorting signal at its carboxyl-terminal end as described above; (2) forming a reaction mixture including: (i) the expressed polypeptide; (ii) a substantially purified sortase-transamidase enzyme; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and (3) allowing the
10 sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX₃X₄G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

15 In this method, the polypeptide having the sorting signal at its carboxy-terminal end need not be expressed in a Gram-positive bacterium; it can be expressed in another bacterial system such as *Escherichia coli* or *Salmonella typhimurium*, or in a eukaryotic expression system.

20 The other method for protein targeting and display relies on direct expression of the chimeric protein in a Gram-positive bacterium and the action of the sortase-transamidase on the expressed protein. In general, such a method comprises the steps of: (1) cloning a nucleic acid segment encoding a chimeric protein into a Gram-positive bacterium to generate a cloned chimeric protein including therein a carboxyl-terminal sorting signal as described above, the chimeric protein including the polypeptide to be displayed; (2) growing the bacterium into which the nucleic acid segment has been cloned to express the cloned chimeric protein to generate a
25 chimeric protein including therein a carboxyl-terminal sorting signal; and (3) covalent binding of the chimeric protein to the cell wall by the enzymatic action of the sortase-transamidase involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the protein is

displayed on the surface of the gram-positive bacterium in such a way that the protein is accessible to a ligand.

Typically, the Gram-positive bacterium is a species of *Staphylococcus*. A particularly preferred species of *Staphylococcus* is *Staphylococcus aureus*.

5 However, other Gram-positive bacteria such as *Streptococcus pyogenes*, other *Streptococcus* species, and Gram-positive bacteria of other genera can also be used.

Cloning the nucleic acid segment encoding the chimeric protein into the Gram-positive bacterium is performed by standard methods. In general, such cloning involves: (1) isolation of a nucleic acid segment encoding the protein to be sorted and covalently linked to the
10 cell wall; (2) joining the nucleic acid segment to the sorting signal; (3) cloning by insertion into a vector compatible with the Gram-positive bacterium in which expression is to take place; and (4) incorporation of the vector including the new chimeric nucleic acid segment into the bacterium.

Typically, the nucleic acid segment encoding the protein to be sorted is DNA; however, the use of RNA in certain cloning steps is within the scope of the present invention.

15 When dealing with genes from eukaryotic organisms, it is preferred to use cDNA, because the natural gene typically contains intervening sequences or introns that are not translated. Alternatively, if the amino acid sequence is known, a synthetic gene encoding the protein to be sorted can be constructed by standard solid-phase oligodeoxyribonucleotide synthesis methods, such as the phosphotriester or phosphite triester methods. The sequence of
20 the synthetic gene is determined by the genetic code, by which each naturally occurring amino acid is specified by one or more codons. Additionally, if a portion of the protein sequence is known, but the gene or messenger RNA has not been isolated, the amino acid sequence can be used to construct a degenerate set of probes according to the known degeneracy of the genetic code. General aspects of cloning are described, for example, in J. Sambrook et al., "Molecular
25 Cloning: A Laboratory Manual" (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989); in B. Perbal, "A Practical Guide to Molecular Cloning" (2d ed., John Wiley & Sons, New York 1988), in S.L. Berger & A.R. Kimmel, "Guide to Molecular Cloning Techniques" (Methods in Enzymology, vol. 152, Academic Press, Inc., San Diego, 1987), and in

D.V. Goeddel, ed., "Gene Expression Technology" (Methods in Enzymology, vol. 185, Academic Press, Inc., San Diego, 1991).

Once isolated, DNA encoding the protein to be sorted is then joined to the sorting signal. This is typically accomplished through ligation, such as using *Escherichia coli* or bacteriophage T4 ligase. Conditions for the use of these enzymes are well known and are described, for example, in the above general references.

The ligation is done in such a way so that the protein to be sorted and the sorting signal are joined in a single contiguous reading frame so that a single protein is produced. This may, in some cases, involve addition or deletion of bases of the cloned DNA segment to maintain a single reading frame. This can be done by using standard techniques.

Cloning is typically performed by inserting the cloned DNA into a vector containing control elements to allow expression of the cloned DNA. The vector is then incorporated into the bacterium in which expression is to occur, using standard techniques of transformation or other techniques for introducing nucleic acids into bacteria.

One suitable cloning system for *S. aureus* places the cloned gene under the control of the BlaZRI regulon (P.Z. Wang et al., Nucl. Acids Res. 19:4000 (1991)). Vectors and other cloning techniques for use in *Staphylococcus aureus* are described in B. Nilsson & L. Abrahmsen, "Fusion to Staphylococcal Protein A," in Gene Expression Technology, supra, p.144-161.

If the chimeric protein is cloned under control of the BlaZRI regulon, expression can be induced by the addition of the β -lactam antibiotic methicillin.

Another aspect of the present invention is a polypeptide displayed on the surface of a Gram-positive bacterium by covalent linkage of an amino-acid sequence of LPX₃X₄ derived from cleavage of an LPX₃X₄G motif, as described above.

Yet another aspect of the present invention is a covalent complex comprising: (1) the displayed polypeptide; and (2) an antigen or hapten covalently cross-linked to the polypeptide.

B. Screening Methods

These polypeptides associated with the cell surfaces of Gram-positive bacteria can be used in various ways for screening. For example, samples of expressed proteins from an expression library containing expressed proteins on the surfaces of the cells can be used to screen
5 for clones that express a particular desired protein when a labeled antibody or other labeled specific binding partner for that protein is available.

These methods are based on the methods for protein targeting and display described above.

A first embodiment of such a method comprises: (1) expressing a cloned
10 polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end as described above; (2) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) a substantially purified sortase-transamidase enzyme; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting
15 signal; (3) binding of the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and (4)
20 reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

The nucleic acid segment encoding the chimeric protein is formed by methods well known in the art and can include a spacer.

In the last step, the cells are merely exposed to the labeled antibody or other
25 labeled specific binding partner, unreacted antibodies removed as by a wash, and label associated with the cells detected by conventional techniques such as fluorescence, chemiluminescence, or autoradiography.

A second embodiment of this method employs expression in a Gram-positive bacterium that also produces a sortase-transamidase enzyme. This method comprises: (1) cloning a nucleic acid segment encoding a chimeric protein into a Gram-positive bacterium to

generate a cloned chimeric protein including therein a carboxyl-terminal sorting signal as described above, the chimeric protein including the polypeptide whose expression is to be screened; (2) growing the bacterium into which the nucleic acid segment has been cloned to express the cloned chimeric protein to generate a chimeric protein including therein a carboxyl-terminal sorting signal; (3) binding the polypeptide covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and (4) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

V. USE OF SORTED MOLECULES FOR DIAGNOSIS AND TREATMENT OF BACTERIAL INFECTIONS

Sorted molecules can also be used for the diagnosis and treatment of bacterial infections caused by Gram-positive bacteria. Antibiotic molecules or fluorescent or any other diagnostic molecules can be chemically linked to a sorted peptide segment, which may include a spacer as described above, and then can be injected into animals or humans. These molecules are then sorted by the sortase-transamidase so that they are covalently linked to the cell wall of the bacteria.

In general, these methods comprise: (1) conjugating an antibiotic or a detection reagent to a protein including therein a carboxyl-terminal sorting signal to produce a conjugate; and (2) introducing the conjugate to an organism infected with a Gram-positive bacterium in order to cause the conjugate to be sorted and covalently cross-linked to the cell walls of the bacterium in order to treat or diagnose the infection.

The antibiotic used can be, but is not limited to, a penicillin, ampicillin, vancomycin, gentamicin, streptomycin, a cephalosporin, amikacin, kanamycin, neomycin, paromomycin, tobramycin, ciprofloxacin, clindamycin, rifampin, chloramphenicol, or norfloxacin, or a derivative of these antibiotics.

The detection reagent is typically an antibody or other specific binding partner labeled with a detectable label, such as a radiolabel. Such methods are well known in the art and need not be described further here.

Accordingly, another aspect of the present invention is a conjugate comprising an
5 antibiotic or a detection reagent covalently conjugated to a protein including therein a carboxyl-terminal sorting signal as described above to produce a conjugate.

Yet another aspect of the present invention is a composition comprising the conjugate and a pharmaceutically acceptable carrier.

In this context, the conjugates can be administered using conventional modes of
10 administration, including, but not limited to, intravenous, intraperitoneal, oral, or intralymphatic. Other routes of administration can alternatively be used. Oral or intraperitoneal administration is generally preferred. The composition can be administered in a variety of dosage forms, which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders,
15 suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends on the mode of administration and the quantity administered.

The compositions for administration preferably also include conventional
pharmaceutically acceptable carriers and adjuvants known in the art such as human serum
albumin, ion exchangers, alumina, lecithin, buffered substances such as phosphate, glycine,
20 sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate. The most effective mode of administration and dosage regimen for the conjugates as used in the methods in the present invention depend on the severity and course of the disease, the patient's health, the response to treatment, the particular strain of bacteria infecting the patient, other drugs being administered and the development of resistance to them, the accessibility of the site of infection
25 to blood flow, pharmacokinetic considerations such as the condition of the patient's liver and/or kidneys that can affect the metabolism and/or excretion of the administered conjugates, and the judgment of the treating physician. According, the dosages should be titrated to the individual patient.

VI. USE OF SORTED POLYPEPTIDES FOR PRODUCTION OF VACCINES

Additionally, the sorted polypeptides covalently crosslinked to the cell walls of Gram-positive bacteria according to the present invention have a number of uses. One use is use in the production of vaccines that can be used to generate immunity against infectious diseases affecting mammals, including both human and non-human mammals, such as cattle, sheep, and goats, as well as other animals such as poultry and fish. This invention is of special importance to mammals. The usefulness of these complexes for vaccine production lies in the fact that the proteins are on the surface of the cell wall and are accessible to the medium surrounding the bacterial cells, so that the antigenic part of the chimeric protein is accessible to the antigen processing system. It is well known that presenting antigens in particulate form greatly enhances the immune response. In effect, bacteria containing antigenic peptides on the surfaces linked to the bacteria by these covalent interactions function as natural adjuvants. Here follows a representative list of typical microorganisms that express polypeptide antigens against which useful antibodies can be prepared by the methods of the present invention:

(1) Fungi: *Candida albicans*, *Aspergillus fumigatus*, *Histoplasma capsulatum* (all cause disseminating disease), *Microsporium canis* (animal ringworm).

(2) Parasitic protozoa: (1) *Plasmodium falciparum* (malaria), *Trypanosoma cruzi* (sleeping sickness).

(3) Spirochetes: (1) *Borrelia burgdorferi* (Lyme disease), *Treponema pallidum* (syphilis), *Borrelia recurrentis* (relapsing fever), *Leptospira icterohaemorrhagiae* (leptospirosis).

(4) Bacteria: *Neisseria gonorrhoeae* (gonorrhea), *Staphylococcus aureus* (endocarditis), *Streptococcus pyogenes* (rheumatic fever), *Salmonella typhosa* (salmonellosis), *Hemophilus influenzae* (influenza), *Bordetella pertussis* (whooping cough), *Actinomyces israelii* (actinomycosis), *Streptococcus mutans* (dental caries), *Streptococcus equi* (strangles in horses), *Streptococcus agalactiae* (bovine mastitis), *Streptococcus anginosus* (canine genital infections).

(5) Viruses: Human immunodeficiency virus (HIV), poliovirus, influenza virus, rabies virus, herpes virus, foot and mouth disease virus, psittacosis virus, paramyxovirus, myxovirus, coronavirus.

Typically, the resulting immunological response occurs by both humoral and cell-mediated pathways. One possible immunological response is the production of antibodies, thereby providing protection against infection by the pathogen.

This method is not limited to protein antigens. As discussed below, non-protein antigens or haptens can be covalently linked to the C-terminal cell-wall targeting segment, which can be produced as an independently expressed polypeptide, either alone, or with a spacer at its amino-terminal end. If a spacer at the amino-terminal end is used, typically the spacer will have a conformation allowing the efficient interaction of the non-protein antigen or hapten with the immune system, most typically a random coil or α -helical form. The spacer can be of any suitable length; typically, it is in the range of about 5 to about 30 amino acids; most typically, about 10 to about 20 amino acids. In this version of the embodiment, the independently expressed polypeptide, once expressed, can then be covalently linked to the hapten or non-protein antigen. Typical non-protein antigens or haptens include drugs, including both drugs of abuse and therapeutic drugs, alkaloids, steroids, carbohydrates, aromatic compounds, including many pollutants, and other compounds that can be covalently linked to protein and against which an immune response can be raised.

Alternatively, a protein antigen can be covalently linked to the independently expressed cell-wall targeting segment or a cell-wall targeting segment including a spacer.

Many methods for covalent linkage of both protein and non-protein compounds to proteins are well known in the art and are described, for example, in P. Tijssen, "Practice and Theory of Enzyme Immunoassays" (Elsevier, Amsterdam, 1985), pp. 221-295, and in S.S. Wong, "Chemistry of Protein Conjugation and Cross-Linking" (CRC Press, Inc., Boca Raton, FL, 1993).

Many reactive groups on both protein and non-protein compounds are available for conjugation.

For example, organic moieties containing carboxyl groups or that can be carboxylated can be conjugated to proteins via the mixed anhydride method, the carbodiimide method, using dicyclohexylcarbodiimide, and the N-hydroxysuccinimide ester method.

If the organic moiety contains amino groups or reducible nitro groups or can be substituted with such groups, conjugation can be achieved by one of several techniques.

Aromatic amines can be converted to diazonium salts by the slow addition of nitrous acid and then reacted with proteins at a pH of about 9. If the organic moiety contains aliphatic amines, such groups can be conjugated to proteins by various methods, including carbodiimide, tolylene-2,4-diisocyanate, or maleimide compounds, particularly the N-hydroxysuccinimide esters of maleimide derivatives. An example of such a compound is 4-(N-maleimidomethyl)-cyclohexane-1-carboxylic acid. Another example is m-maleimidobenzoyl-N-hydroxysuccinimide ester. Still another reagent that can be used is N-succinimidyl-3-(2-pyridyldithio) propionate. Also, bifunctional esters, such as dimethylpimelimidate, dimethyladipimidate, or dimethylsuberimidate, can be used to couple amino-group-containing moieties to proteins.

Additionally, aliphatic amines can also be converted to aromatic amines by reaction with p-nitrobenzoylchloride and subsequent reduction to a p-aminobenzoylamide, which can then be coupled to proteins after diazotization.

Organic moieties containing hydroxyl groups can be cross-linked by a number of indirect procedures. For example, the conversion of an alcohol moiety to the half ester of succinic acid (hemisuccinate) introduces a carboxyl group available for conjugation. The bifunctional reagent sebacoyldichloride converts alcohol to acid chloride which, at pH 8.5, reacts readily with proteins. Hydroxyl-containing organic moieties can also be conjugated through the highly reactive chlorocarbonates, prepared with an equal molar amount of phosgene.

For organic moieties containing ketones or aldehydes, such carbonyl-containing groups can be derivatized into carboxyl groups through the formation of O-(carboxymethyl) oximes. Ketone groups can also be derivatized with p-hydrazinobenzoic acid to produce carboxyl groups that can be conjugated to the specific binding partner as described above.

Organic moieties containing aldehyde groups can be directly conjugated through the formation of Schiff bases which are then stabilized by a reduction with sodium borohydride.

One particularly useful cross-linking agent for hydroxyl-containing organic moieties is a photosensitive noncleavable heterobifunctional cross-linking reagent,

5 sulfosuccinimidyl 6-[4'-azido-2'-nitrophenylamino] hexanoate. Other similar reagents are described in S.S. Wong, "Chemistry of Protein Conjugation and Cross-Linking," supra.

Other cross-linking reagents can be used that introduce spacers between the organic moiety and the specific binding partner.

These methods need not be described further here.

10 VII. PRODUCTION OF SUBSTANTIALLY PURIFIED SORTASE-TRANSAMIDASE ENZYME

Another aspect of the present invention is methods for the production of substantially purified sortase-transamidase enzyme.

15 A. Methods Involving Expression of Cloned Gene

One method for the production of substantially purified sortase-transamidase enzyme involves the expression of the cloned gene, preferably the *srtA* gene. The isolation of the nucleic acid segment or segments encoding the sortase-transamidase enzyme is described
20 above; these nucleic acid segment or segments are then incorporated into a vector and then use to transform a host in which the enzyme can be expressed. In one alternative, the host is a Gram-positive bacterium.

The next step in this alternative is expression in a Gram-positive bacterium to generate the cloned sortase-transamidase enzyme. Expression is typically under the control of
25 various control elements associated with the vector incorporating the DNA encoding the sortase-transamidase gene, such as the coding region of the *srtA* gene; such elements can include promoters and operators, which can be regulated by proteins such as repressors. The conditions required for expression of cloned proteins in gram-positive bacteria, particularly *S. aureus*, are

well known in the art and need not be further recited here. An example is the induction of expression of lysostaphin under control of the BlaZRI regulon induced by the addition of methicillin.

When expressed in *Staphylococcus aureus*, the chimeric protein is typically first exported with an amino-terminal leader peptide, such as the hydrophobic signal peptide at the amino-terminal region of the cloned lysostaphin of Recsei et al. (P. Recsei et al., "Cloning, Sequence, and Expression of the Lysostaphin Gene from *Staphylococcus simulans*," Proc. Natl. Acad. Sci. USA 84:1127-1131 (1987)).

Alternatively, the cloned nucleic acid segment encoding the sortase-transamidase enzyme can be inserted in a vector that contains sequences allowing expression of the sortase-transamidase in another organism, such as *E. coli* or *S. typhimurium*. A suitable host organism can then be transformed or transfected with the vector containing the cloned nucleic acid segment. Expression is then performed in that host organism.

The expressed enzyme is then purified using standard techniques. Techniques for the purification of cloned proteins are well known in the art and need not be detailed further here. One particularly suitable method of purification is affinity chromatography employing an immobilized antibody to sortase. Other protein purification methods include chromatography on ion-exchange resins, gel electrophoresis, isoelectric focusing, and gel filtration, among others.

One particularly useful form of affinity chromatography for purification of cloned proteins, such as sortase-transamidase, as well as other proteins, such as glutathione S-transferase and thioredoxin, that have been extended with carboxyl-terminal histidine residues, is chromatography on a nickel-sepharose column. This allows the purification of a sortase-transamidase enzyme extended at its carboxyl terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to the nickel-sepharose column through the histidine residues. The bound protein is then eluted with imidazole. Typically, six or more histidine residues are added; preferably, six histidine residues are added. One way of adding the histidine residues to a cloned protein, such the sortase-transamidase, is through PCR with a primer that includes nucleotides encoding the histidine residues. The histidine codons are

CAU and CAC expressed as RNA, which are CAT and CAC as DNA. Amplification of the cloned DNA with appropriate primers will add the histidine residues to yield a new nucleic acid segment, which can be recloned into an appropriate host for expression of the enzyme extended with the histidine residues.

5

B. Other Methods

Alternatively, the sortase-transamidase can be purified from Gram-positive bacteria by standard methods, including precipitation with reagents such as ammonium sulfate or protamine sulfate, ion-exchange chromatography, gel filtration chromatography, affinity
10 chromatography, isoelectric focusing, and gel electrophoresis, as well as other methods known in the art.

Because the sortase-transamidase is a cysteine protease, one particularly useful method of purification involves covalent chromatography by thiol-disulfide interchange, using a two-protonic-state gel containing a 2-mercaptopyridine leaving group, such as Sepharose 2B-glutathione 2-pyridyl disulfide or Sepharose 6B-hydroxypropyl 2-pyridyl disulfide. Such
15 covalent chromatographic techniques are described in K. Brocklehurst et al., "Cysteine Proteases," in New Comprehensive Biochemistry, Volume 16: Hydrolytic Enzymes (A. Neuberger & K. Brocklehurst, eds., Elsevier, New York, 1987), ch. 2, pp. 39-158.

20 VIII. FURTHER APPLICATIONS OF SORTASE-TRANSAMIDASE

A. Production of Antibodies

Antibodies can be prepared to the substantially purified sortase-transamidase of the present invention, whether the sortase-transamidase is purified from bacteria or produced from recombinant bacteria as a result of gene cloning procedures. Because the substantially
25 purified enzyme according to the present invention is a protein, it is an effective antigen, and antibodies can be made by well-understood methods such as those disclosed in E. Harlow & D. Lane, "Antibodies: A Laboratory Manual" (Cold Spring Harbor Laboratory, 1988). In general, antibody preparation involves immunizing an antibody-producing animal with the protein, with

or without an adjuvant such as Freund's complete or incomplete adjuvant, and purification of the antibody produced. The resulting polyclonal antibody can be purified by techniques such as affinity chromatography.

Once the polyclonal antibodies are prepared, monoclonal antibodies can be prepared by standard procedures, such as those described in Chapter 6 of Harlow & Lane, supra.

B. Derivatives for Affinity Chromatography

Another aspect of the present invention is derivatives of the cloned, substantially purified sortase-transamidase of the present invention extended at its carboxyl terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column through the histidine residues. Typically, six or more histidine residues are added; preferably, six histidine residues are added.

The histidine residues can be added to the carboxyl terminus through PCR cloning as described above.

This invention is further described by means of the following example. This Example is for illustrative purposes only, and are not to be construed as limiting the scope of the invention in any manner.

Example 1Identification of a Staphylococcal Mutant Defective in Cell Wall SortingGeneration of temperature sensitive (ts) mutants through chemical mutagenesis

5 Cell wall sorting mutants were created and isolated from a population of conditional lethal mutants of *S. aureus* strain OS2. Staphylococci were mutagenized with nitrosoguanidine and colonies were formed by plating at 30°C. Bacteria were streaked and incubated at 30°C and 42°C to identify mutants that are temperature sensitive for growth (ts). A collection of one thousand ts mutants was transformed with pSEB-SPA490-524 (O. Schneewind, 10 D. Mihaylova-Petkov, P. Model, *EMBO* 12, 4803 (1993)), specifying a reporter protein for measurements of surface protein anchoring. The SEB-SPA490-524 precursor (P1) is exported from the cytoplasm and its NH₂-terminal leader peptide removed to generate the P2 intermediate (Figure 2A). The P2 precursor is the substrate for sortase, which cleaves the polypeptide between the threonine and the glycine of the LPXTG motif and generates mature, anchored 15 surface protein (M). When analyzed by labeling wild-type staphylococci with [³⁵S]methionine for 5 min, cleavage of P1 precursor is faster than that of the P2 species, yielding a ratio of P1 (5%), P2 (19%), and M(76%) concentration (Figure 2B). This assay was employed to screen one thousand ts mutants and two strains were identified that accumulated P2 precursor at 47% (SM317) and 26% (SM329), respectively (Figure 2B). To examine the sorting reaction further, 20 mutant and wild-type staphylococci were subjected to pulse-chase analysis (Figure 2C). *S. aureus* OS2 (wild-type) cleaved and anchored the P1 precursor within 2 min. The sorting reaction in strain SM317 was severely reduced as cleavage and cell wall anchoring of pulse-labeled P2 required more than 10 min. Strain SM329 displayed only a weak defect and P2 processing required 3 min (Figure 2C). When examined by pulse-labeling staphylococci grown 25 in minimal medium, SM329 displayed a much more severe defect in cell wall sorting.

Anchor structure of surface proteins in the mutant strain SM317

To examine whether the mutant strains SM317 and SM329 are defective in the synthesis of bacterial cell wall, two tests were performed. Lysostaphin is a bacteriolytic enzyme that cuts the pentaglycine crossbridges of the staphylococcal cell wall predominantly at the central glycine residue (C. A. Schindler and V. T. Schuhardt, *Proc. Natl. Acad. Sci. USA* **51**, 414 (1964); B. L. M. de Jonge, Y. S. Chang, D. Gage, A. Tomasz, *J. Biol. Chem.* **267**, 11248 (1992)). As reported previously, *fem* mutants display resistance to this bacteriocin and grow even in the presence of large amounts of lysostaphin (U. Kopp, M. Roos, J. Wecke, H. Labischinski, *Microb. Drug Resist.* **2**, 29 (1996)). Strains SM317 and SM329 were sensitive to lysostaphin at concentrations that also inhibited growth of wild-type staphylococci, indicating that the sorting defect in SM317 is not caused by a mutationally altered cell wall crossbridge. To measure bacterial cell wall synthesis, staphylococci were grown in minimal medium and labeled with [³H]lysine and [³H]leucine (D. Boothby, L. Daneo-Moore, G. D. Shockman, *Anal. Biochem.* **44**, 645 (1971)). As lysine, but not leucine, is a component of the bacterial cell wall, the ratio of [³H]lysine/[³H]leucine incorporation into acid precipitable and protease resistant murein polymer is a measure for cell wall synthesis (D. Boothby, L. Daneo-Moore, G. D. Shockman, *Anal. Biochem.* **44**, 645 (1971)). Wild-type staphylococci displayed a ratio of 30, while the addition of vancomycin to the culture medium reduced the ratio of incorporated lysine/leucine to 1.5 (20 fold inhibition). Strains SM317 and SM329 displayed a ratio of 18 and 19 (1.6 fold less than wild-type cells), suggesting that the accumulation of P2 precursor in the mutant SM317 is not caused by a defect in cell wall synthesis.

The cell wall anchor structure of surface protein in strain SM317 was determined (Figure 3). Plasmid pHTT4 specifying the reporter protein SEB-MH₆-CWS was transformed into *S. aureus* SM317 (H. Ton-That, K. F. Faull, O. Schneewind, *J. Biol. Chem.* **272**, 22285 (1997)). The staphylococcal cell wall was purified and digested with mutanolysin, a muramidase that hydrolyzes the glycan strands (K. Yokogawa, *et al.*, *Antimicrob. Agents Chemother.* **6**, 156 (1974)). Mutanolysin-released surface protein was purified by chromatography on Ni-NTA and cleaved at methionine residues with cyanogen bromide (H. Ton-That, K. F. Faull, O.

Schneewind, *J. Biol. Chem.* **272**, 22285 (1997)). COOH-terminal peptides bearing cell wall anchor structures were purified by a second affinity chromatography step and analyzed by MALDI-MS (Figure 3B). A series of ion signals with regularly spaced mass increments was revealed, measurements that are consistent with one, two, three, four, five and six peptidoglycan subunits linked to the COOH-terminal threonine of surface protein. Ion signals of muanolysin-solubilized anchor peptides were explained as H₆AQALPET-Gly₅ linked to cell wall tetrapeptide (predicted mass 2235; observed 2236), pentapeptide (predicted mass 2306; observed 2306), N,O6-diacetylMurNac-GlcNac tetrapeptide (predicted mass 2755, observed 2756), N,O6-diacetylMurNac-GlcNac pentapeptide (predicted mass 2826, observed 2826), murein-tetrapeptide-murein-pentapeptide (predicted mass 3991, observed 3995), (murein-tetrapeptide)₂-murein-pentapeptide (predicted mass 5194; observed 5196), (murein-tetrapeptide)₄ (predicted mass 6285 observed 6285), (murein-tetrapeptide)₄-murein-pentapeptide (predicted mass 7581; observed 7583), (murein-tetrapeptide)₅-murein-pentapeptide (predicted mass 8783; observed 8784). If surface protein is tethered to cross-linked peptidoglycan of strain SM317, digestion of muramidase-solubilized anchor peptides with *f*11 hydrolase should produce anchor peptide linked to murein tetrapeptide and disaccharide-tetrapeptide (H. Ton-That, K. F. Faull, O. Schneewind, *J. Biol. Chem.* **272**, 22285 (1997); W. W. Navarre, H. Ton-That, K. F. Faull, O. Schneewind, *J. Biol. Chem.* **274**, in press (1999)) (Figure 3). This was tested and the doubly digested anchor peptides generated ion signals at *m/z* 2236 [L-Ala-D-iGln-L-Lys(NH₂-H₆AQALPET-Gly₅)-D-Ala, predicted mass 2235], 2714 [MurNac(L-Ala-D-iGln-L-Lys(NH₂-H₆AQALPET-Gly₅)-D-Ala)-GlcNac, predicted mass 2713] and 2756 [O6-acetyl-MurNac(L-Ala-D-iGln-L-Lys(NH₂-H₆AQALPET-Gly₅)-D-Ala)-GlcNac, predicted mass 2756] (Figure 3C). Thus, surface proteins of *S. aureus* SM317 are tethered to cross-linked peptidoglycan in a manner that is indistinguishable from the anchor structure of polypeptides in wild-type staphylococci (W. W. Navarre, H. Ton-That, K. F. Faull, O. Schneewind, *J. Biol. Chem.* **273**, 29135 (1998)). These results suggest that the accumulation of P2 precursor in strain SM317 is likely caused by a defect in sortase.

Screening for the Sortase Gene

Over-expression of sortase from a multi-copy plasmid should reduce the concentration of P2 in both wild-type and mutant staphylococci. A plasmid library of two thousand 3-5 kb random *S. aureus* OS2 chromosomal DNA insertions was screened for sequences that caused a reduction in the concentration of P2 precursor in strain SM317. Two plasmids, pGL1631 and pGL1834, answered this screen (Figure 4). Transformation with pGL1834 reduced the P2 concentration in strain SM317 from 44% to 9%, in strain SM329 from 26% to 12%, and in wild-type *S. aureus* OS2 from 17% to 8%. When measured by pulse-chase analysis, *S. aureus* OS2 (pGL1834) displayed a rapidly increased processing of P2 precursors, a phenotype that was also observed in strains SM317 and SM329 (Figure 4C). DNA sequencing revealed that pGL1631 and pGL1834 contained staphylococcal chromosomal DNA insertions with identical overlapping sequences. The DNA sequence sufficient to promote a reduction in P2 concentration was mapped to a gene which was named *srtA* (surface protein sorting A) (Figure 5).

The *srtA* gene

The *srtA* gene (SEQ. ID NO. 2) specifies a polypeptide chain of 206 amino acids (Figure 6; SEQ. ID. NO. 3). A sequence of 18 hydrophobic amino acids near the NH₂-terminus suggests the presence of a signal peptide/membrane anchor sequence. This feature is consistent with the notion that cell wall anchoring occurs on the cell surface, after polypeptide substrates bearing an LPXTG motif have been translocated across the cytoplasmic membrane. Another property of the *srtA* gene consistent with its function as sortase is the presence of codon 184 specifying cysteine. As the cell wall sorting reaction is sensitive to methanethiosulfonate, a reagent that forms disulfide with sulfhydryl (D.J. Smith, E.T. Maggio, G.L. Kenyon, *Biochemistry* **14**, 764 (1975)), the presence of a cysteine must be a conserved feature of sortase homologues.

Many, if not all, Gram-positive pathogens display proteins on their surface via a sorting signal mediated mechanism (W. W. Navarre and O. Schneewind, *Microbiol. Mol. Biol.*

Rev. 63, 174 (1999)). Thus, if the *srtA* gene specifies sortase, homologous genes should be found in the genomes of other Gram-positive pathogens. Chromosomal DNA sequences of *Enterococcus faecalis*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, and *Streptococcus mutans* were searched and the presence of *srtA* genes revealed (Figure 7). Database searches also identified sequences homologous to *srtA* in *Bacillus subtilis* and *Actinomyces naeslundii*. All *srtA* homologues displayed absolute conservation of the cysteine and striking conservation of the peptide sequences surrounding it (Figure 7). *S. pneumoniae* harbors more than one *srtA* homologue which we have named *srtB* and *srtC*, respectively. The *srtA* like genes of *E. faecalis* and *A. naeslundii* are immediately adjacent to structural genes specifying surface proteins with a COOH-terminal sorting signal. The presence of a *srtA* homologue in the chromosome of *B. subtilis* is surprising as LPXTG motif containing sorting signals have not yet been identified in this organism. One of the *srtA* homologues in *A. naeslundii*, previously designated *orf365*, has been mutated, which abolished fimbrial assembly of mutant *Actinomyces* (M. K. Yeung, J. A. Donkersloot, J. O. Cisar, P. A. Ragsdale, *J. Bacteriol.* **66**, 1482 (1998)). *Actinomyces* fimbriae are composed of protein subunits bearing LPXTG motifs (M. K. Yeung and J. O. Cisar, *J. Bacteriol.* **172**, 2462 (1990)), however the mechanism of fimbrial assembly (polymerization) is not yet understood.

The *srtA* gene in strain SM317

To examine whether the defect in cell wall sorting of *S. aureus* SM317 is caused by a mutation in the *srtA* gene, corresponding sequences were PCR amplified from the chromosomal DNA of *S. aureus* OS2 and SM317. When cloned into a multi-copy vector and transformed into *S. aureus* SM317, the *srtA* gene amplified from wild-type staphylococci reduced the P2 concentration from 44% to 12%, while the same gene amplified from the chromosomal DNA of *S. aureus* SM317 did not reduce the P2 concentration of the parent strain (Figure 4B). Thus, the *srtA* gene is defective in strain SM317 and DNA sequencing identified mutations in codons 35 and 180. The expression of wild-type *srtA* in SM317 in the ts phenotype of the mutant strain was examined. Multi-copy expression of *srtA* (pGL1894) allowed growth of

SM317 at 42°C albeit at a rate that was less than that observed for wild-type staphylococci. This result suggests that the conditional lethal phenotype of *S. aureus* SM317 is not only caused a mutation in the *srtA* gene. Expression of plasmid encoded wild-type *srtA* did not alter the ts growth phenotype of *S. aureus* SM329.

5

Sortase and the cell wall sorting reaction

The *srtA* gene was isolated as a multi-copy suppressor of P2 precursor accumulation, a scheme that should only be answered by the gene for sortase. Only one gene (*srtA*) from a library of two thousand plasmid transformants bearing random 3-5 kb chromosomal DNA insertions was observed this screen. Additional observations show SrtA protein catalyzes the *in vitro* transpeptidation of substrates bearing an LPXTG motif, thereby demonstrating that SrtA displays sortase activity. Purified SrtA protein can be used for the screening of compounds that inhibit sortase. Such compounds may be useful for the treatment of human infections caused by Gram-positive bacteria.

15

Materials and Methods

Mutagenesis of *S. aureus* Strain OS2

Staphylococci (1×10^{12} cfu) were treated with 0.2 mg/ml N-methyl-N'-nitro-N-nitrosoguanidine for 45 min at 30°C and mutagenesis was quenched by the addition of 2 volumes of 100 mM sodium phosphate, pH 7.0. Approximately 80% of the mutagenized population was killed and the mutational frequency of rifampicin resistant *rpoB* mutations was increased to 1.2×10^{-4} . Temperature sensitive mutants were selected by growing the mutagenized population in tryptic soy broth at 42°C and treating with 8 µg/ml penicillin G for two hours, a selection that was repeated twice. Colonies were formed at 30°C, streaked on tryptic soy agar and examined for growth at 42°C.

25

Transformation of Competent Cells

Staphylococci were grown in tryptic soy broth supplemented with chloramphenicol (10 mg/ml) or tetracycline (2 mg/ml) at 30°C until OD₆₆₀ 0.6. Cells were incubated at 42°C for 20 min, sedimented by centrifugation at 15,000 x g for 3 minutes and washed with 1 ml of prewarmed minimal medium [Schneewind, O., Model, P., Fischetti, V.A. (1992) Cell 70, 267]. Staphylococci were labeled with 50 mCi of [³⁵S]-Promix (Amersham) for 5 minutes and surface protein processing quenched by the addition of 75 ml 100% TCA. The TCA precipitates were collected by centrifugation, washed in acetone and dried under vacuum. Samples were suspended in 1 ml of 0.5 M Tris-HCl, pH 7.0 and staphylococcal peptidoglycan was digested by adding 50 ml 2 mg/ml lysostaphin (AMBI Pharmaceuticals) for 1 hour at 37°C. Proteins were again precipitated with TCA, washed with acetone and, after immunoprecipitation with a-SEB, were analyzed by 14% SDS-PAGE and PhosphorImager.

Pulse-Chase Screen of Mutants

Staphylococci were grown as described above and 5 ml were labeled with 500 mCi of [³⁵S]-Promix (Amersham) for 45 seconds. Incorporation of radioactivity was quenched by adding 50 ml chase (100 mg/ml casamino acids, 20 mg/ml methionine and cysteine). At timed intervals after the addition of the chase, 1 ml aliquots were removed and protein was precipitated by the addition of 75 ml 100% TCA. Sample preparation followed the same steps as described above.

DNA Sequencing

The DNA insertions pf pGL1631 and 1834 were mapped and sequenced by synthesizing oligonucleotide primers that annealed to sequenced template DNA 500 nucleotides apart. The primers for the amplification of *srtA* from the chromosomal DNA of *S. aureus* strains OS2 and SM317 were 5'-AAGGATTCAAAAGGAGCGGTATACATTGC-3' (SEQ ID NO. 32) and 5'-AAGGATCCTACCTTTTCCTCTAGCTGAAC-3' (SEQ ID NO. 33).

EXAMPLE 2

Inhibitors of Cell Wall Sorting

To study the effects of antibiotic cell wall synthesis inhibitors interfered with the anchoring of surface proteins, the activity of several inhibitors were examined in a Gram-positive bacteria sorting assay. A search for chemical inhibitors of the sorting reaction identified methanethiosulfonates and p-hydroxymercuribenzoic acid. Thus, sortase, the enzyme proposed to cleave surface proteins at the LPXTG motif, appears to be a sulfhydryl containing enzyme that utilizes peptidoglycan precursors but not assembled cell wall as a substrate for the anchoring of surface protein.

In order to identify compounds that interfere with the anchoring of surface proteins a reporter protein Seb-Spa490-524 which, when expressed in *S. aureus* OS2 cells, is synthesized as a precursor in the cytoplasm and initiated into the secretory pathway by an NH₂-terminal leader peptide (P1 precursor) was utilized (Schneewind, O., Mihaylova-Petkov, D. and Model, P. (1993) *EMBO* **12**, 4803-4811). After signal peptide cleavage, the P2 precursor bearing a COOH-terminal sorting signal serves as a substrate for sortase, an enzyme that cleaves between the threonine and the glycine of the LPXTG motif (Navarre, W. W. and Schneewind, O. (1994) *Mol. Microbiol.* **14**, 115-121). Amide linkage of the carboxyl of threonine to the cell wall crossbridge generates mature, anchored surface protein (M) (Schneewind, O., Fowler, A. and Faull, K. F. (1995) *Science* **268**, 103-106). Surface protein processing was investigated by pulse-labeling polypeptides with [³⁵S]methionine. During the pulse, all three species, P1 and P2 precursors as well as mature Seb-Spa490-524 can be detected (Figure 8B). Within 1 min after the addition of the chase, most pulse-labeled surface protein was converted to the mature, anchored species. Surface protein anchoring was complete 3 min after the quenching of [³⁵S]methionine incorporation.

Sodium azide is an inhibitor of SecA, an essential component of the secretory pathway in bacteria (Oliver, D. B., Cabelli, R. J., Dolan, K. M. and Jarosik, G. P. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 8227-8231). Addition of 5 mM sodium azide to staphylococcal cultures

5 min prior to pulse-labeling significantly reduced protein export and led to the accumulation of leader peptide bearing P1 precursor (Schneewind, O., Model, P. and Fischetti, V. A. (1992) *Cell* 70, 267-281). Methanethiosulfonates react with sulfhydryl (Akabas, M. H. and Karlin, A. (1995) *Biochemistry* 34, 12496-12500) and one of these compounds, [2-(trimethylammonium) ethyl]methanethiosulfonate) (MTSET) prevented incorporation of [³⁵S]methionine by staphylococci. However, when added 15 seconds after the beginning of the pulse, MTSET interfered with the cleavage of sorting signals at the LPXTG motif, while the Sec-dependent export of P1 precursor remained unaltered. This result revealed that sortase must harbor a sulfhydryl that is necessary for enzymatic cleavage at LPXTG bearing sorting signals.

Sortase's requirement on sulfhydryl for enzymatic activity was tested, by the addition of other sulfhydryl reagents and analysis of inhibition of the cleavage of sorting signals at the LPXTG motif. MTSES, another methanethiosulfonate also interfered with sorting albeit not as effectively as MTSET (Table I). pHMB, an organic mercurial known to inhibit cysteine proteases, also displayed an inhibitory effect, whereas alkylating reagents such as N-ethylmaleimide, iodoacetate and iodoacetamide did not (Creighton, T. E. (1993) *Proteins*. W.H. Freeman and Company, New York.). Sulfhydryl reducing agents, i.e. dithiothreitol and mercaptoethanol, did not affect the sorting reaction. Neither PMSF, which reacts with hydroxyl (Creighton, T. E. (1993) *Proteins*. W.H. Freeman and Company, New York), nor treatment with the divalent cation chelator EDTA interfered with cell wall sorting, indicating that sortase likely does not require divalent cations or hydroxyl for cleavage and anchoring of surface protein.

Antibiotic inhibition of bacterial cell wall synthesis and cell wall sorting

To examine the effect of known antibiotics on cell wall sorting three compounds, penicillin, vancomycin and moenomycin were used. *S. aureus* OS2 (pSeb-Spa490-524) was grown in minimal medium until A₆₀₀ of 0.3, treated with 10 µg/ml of either penicillin, vancomycin, or moenomycin and incubated for an additional 5 hours (Figure 9A). At 30 min intervals during this experiment, aliquots were withdrawn for measurements of surface protein sorting and cell wall synthesis. The effect of antibiotics on the rate of bacterial cell wall

synthesis was determined as the ratio of [^3H]lysine/[^3H]leucine label incorporated into acid precipitable, pronase resistant peptidoglycan. Lysine is a component of peptidoglycan, whereas leucine is not. Hence, the ratio of incorporation of these two amino acids is a measure for cell wall synthesis. Surface protein anchoring was measured by pulse-labeling and quantified as the ratio between the concentration of P2 precursor [P2] and mature, anchored Seb-Spa490-524 [M].

Addition of vancomycin, penicillin or moenomycin reduced the growth rate of staphylococci as compared to a mock treated control. While the rate of cell wall sorting precursor cleavage remained constant during the growth of mock treated staphylococci, the addition of vancomycin led to a steady accumulation of P2 precursor, indicating that this compound caused a reduction of the sorting reaction. A similar, albeit weaker effect was observed when moenomycin was added to staphylococcal cultures. In contrast, penicillin G did not alter the rate of cell wall sorting. As expected, all three antibiotics diminished the rate of peptidoglycan synthesis (Table II). Together these data revealed that vancomycin and moenomycin cause a reduction in the rate of cell wall sorting, while penicillin had no effect on surface protein anchoring.

Cell wall sorting in staphylococcal protoplasts

Previous work revealed that protoplasts, generated by muralytic digestion of staphylococci or penicillin selection of streptococcal L forms, secreted surface protein into the surrounding medium (van de Rijn, I. and Fischetti, V. A. (1981) *Infect. Immun.* **32**, 86-91; Movitz, J. (1976) *Eur. J. Biochem.* **68**, 291-299). This can be explained in two ways. Either the C-terminal sorting signals cannot retain surface proteins in the envelope of protoplasts or the presence of intact, assembled cell wall is not required to cleave sorting signals at their LPXTG motif. To distinguish between these possibilities, the surface protein anchoring in intact bacteria and staphylococcal protoplasts was measured (Figure 10). Wild-type staphylococci cleaved the Seb-Cws-BlaZ precursor to generate the mature, anchored NH₂-terminal Seb and COOH-terminal, cytoplasmic BlaZ fragments (Navarre, W. W. and Schneewind, O. (1994) *Mol. Microbiol.* **14**, 115-121). When tested in staphylococcal protoplasts generated by lysostaphin-

digestion of the cell wall, precursor cleavage occurred similar to whole cells, indicating that the presence of mature, assembled cell wall is not required for cleavage of sorting signals. Unique sorting products in protoplasts that migrated more slowly than mature, anchored Seb (see arrow in Figure 10B) were observed. As these species were immunoprecipitated with a-Seb but not with a-BlaZ, they likely represent products of the sorting reaction. The COOH-terminal anchor structure of these protoplast species are distinct from those generated by lysostaphin-digestion (three glycyl attached to the carboxyl of threonine), as they migrated more slowly on SDS-PAGE than lysostaphin-released Seb.

To examine whether all cleaved Seb fragments were released into the extra-cellular medium, pulse-labeled protoplasts were sedimented by centrifugation and separated from the extra-cellular medium in the supernatant. All Seb-Cws-BlaZ precursor and COOH-terminal BlaZ cleavage fragment sedimented with the protoplasts. In contrast, NH₂-terminal Seb fragments that migrated at the same speed as Seb released by lysostaphin-digestion from the cell wall of intact staphylococci were soluble in the culture medium. Some, but not all, of the more slowly migrating Seb species sedimented into the pellet, suggesting that these products of the sorting reaction may be attached to protoplast membranes. No precursor cleavage was observed for Seb-CwsDLPXTG-BlaZ in either whole cells or staphylococcal protoplasts.

Materials and Methods

Bacterial Strains and Plasmids

Plasmids pSeb-Spa490-524(3), pSeb-Csw-BlaZ, and pSeb-CwsDLPXTG-BlaZ (Navarre, W. W. and Schneewind, O. (1994) *Mol. Microbiol.* **14**, 115-121) were transformed into *S. aureus* OS2 (*spa:ermC*, *r⁻*) (Schneewind, O., Model, P. and Fischetti, V. A. (1992) *Cell* **70**, 267-281) and have been described previously. Staphylococci were generally grown in tryptic soy broth or agar. All chemicals were purchased from Sigma unless indicated otherwise.

Characterization of Cell Wall Sorting Intermediates

S. aureus OS2 (pSeb-Spa490-524) was grown overnight in CDM (van de Rijn, I. and Kessler, R. E. (1980) *Infect. Immun.* **27**, 444-448) (Jeol BioSciences) supplemented with chloramphenicol (10 mg/ml), diluted 1:10 into minimal medium and grown with shaking at 37°C until *A*₆₀₀ 0.6. Cells were labeled with 100 mCi of [³⁵S]-Promix (Amersham) for 1 minute. Labeling was quenched by the addition of an excess non-radioactive amino acid [50 ml chase (100 mg/ml casamino acids, 20 mg/ml methionine and cysteine)]. At timed intervals after the addition of the chase, 0, 1, 3, and 10 minutes, 250 ml aliquots were removed and protein was precipitated by the addition of 250 ml 10% TCA. The precipitate was sedimented by centrifugation 15,000 x *g* for 10 min, washed with 1 ml acetone and dried. Samples were suspended in 1 ml of 0.5 M Tris-HCl, pH 6.8 and staphylococcal peptidoglycan was digested by adding 50 ml lysostaphin (Schindler, C. A. and Schuhardt, V. T. (1964) *Proc. Natl. Acad. Sci. USA* **51**, 414-421) (100 mg, AMBI Pharmaceuticals) and incubating for 1 hour at 37°C. Proteins were again precipitated with TCA, washed with acetone and subjected to immunoprecipitation with a-Seb followed by SDS-PAGE and PhosphorImager analysis. To characterize the P1 and P2 precursors, 1 ml of culture was either incubated with 5 mM sodium azide for 5 min prior to labeling or 5 mM MTSET was added 15 seconds after the beginning of the pulse.

Antibiotic Inhibition of Cell Wall Sorting

Overnight cultures of *S. aureus* OS2 (pSeb-Spa490-524) grown in CDM were diluted into fresh minimal medium and incubated for until *A*₆₀₀ 0.3. Cultures were then treated with either penicillin (10 mg/ml), vancomycin (10 mg/ml), moenomycin (10 mg/ml) or left untreated. A 0.5 ml culture sample was removed for pulse labeling with 100 mCi of [³⁵S]-Promix (Amersham) for 5 minutes. Labeling was quenched and proteins precipitated by the addition of 0.5 ml 10% TCA. The precipitate was collected by centrifugation, washed in acetone and dried under vacuum. The pellets were suspended in 1 ml 0.5 M Tris-HCl, pH 7.0, 50 ml lysostaphin (100 mg/ml, AMBI Pharmaceuticals) added and the staphylococcal cell wall digested

by incubating for 1 hour at 37°C. Proteins were precipitated with TCA, washed in acetone, dried and solubilized in 50 ml 0.5 M Tris-HCl, pH 7.5, 4% SDS and boiled for 10 min. Aliquots of solubilized surface protein were immunoprecipitated with a-Seb followed by SDS-PAGE and PhosphorImager analysis.

5

Peptidoglycan Synthesis Measurements

Staphylococci were grown in the presence or absence of antibiotics as described above. At 30 min intervals, 0.5 ml culture samples were withdrawn and labeled with either 50 mCi [³H]lysine or 50 mCi [³H]leucine for 20 min (Boothby, D., Daneo-Moore, L. and Shockman, G. D. (1971) *Anal. Biochem.* **44**, 645-653). All labeling was quenched by the addition of 0.5 ml 20% TCA. Samples were heated to 96°C for 30 min, cooled to room temperature and pipetted onto glass fiber filters. The filters were placed into a holder and washed under vacuum suction with 25 ml 75% ethanol and 2 ml 50 mM Tris-HCl, pH 7.8. After incubation in 5 ml pronase solution (50 mM Tris-HCl, pH 7.8, 1 mg/ml pronase) at 30°C for 30 min, filters were washed again with 4 ml of distilled water and 4 ml ethanol. The amount of radioactivity retained by the filter was determined by scintillation counting (Boothby, D., Daneo-Moore, L. and Shockman, G. D. (1971) *Anal. Biochem.* **44**, 645-653).

10

15

Chemical Inhibitors of the Sorting Reaction

S. aureus OS2 (pSeb-Spa490-524) was grown overnight in CDM supplemented with chloramphenicol (10 mg/ml), diluted 1:10 into minimal medium and grown with shaking at 37°C until *A*₆₀₀ 0.6. Cells were labeled with 100 mCi of [³⁵S]-Promix (Amersham) for 5 minutes. Chemicals were added to a final concentration of 5 mM 15 seconds after the beginning of the pulse. All labeling was quenched by adding TCA to 10%. Precipitated cells and proteins were collected by centrifugation, washed in acetone and the staphylococcal cell wall digested with lysostaphin as described above. The digests were again precipitated with TCA, immunoprecipitated with a-Seb followed by SDS-PAGE and PhosphorImager analysis.

20

25

Cell Wall Sorting in Staphylococcal Protoplasts

Overnight cultures of *S. aureus* OS2 (pSeb-Cws-BlaZ) or *S. aureus* OS2 (pSeb-CwsDLPXTG-BlaZ) grown in CDM were diluted 1:10 into minimal medium and grown with shaking at 37°C until A_{600} 0.6. One ml of culture was pulse-labeled with 100 mCi of [³⁵S]-Promix (Amersham) for 2 minutes and labeling was quenched by the addition of 50 ml chase solution. Culture aliquots (0.5 ml) were removed for TCA precipitation either during the pulse or 20 min after the addition of chase. Another culture aliquot was first converted to protoplasts and then subjected to labeling. The cells were sedimented by centrifugation at 15,000 xg for 5 min and suspended in 1 ml 50 mM Tris-HCl, 0.4 M sucrose, 10 mM MgCl₂, pH 7.5. The cell wall was digested with lysostaphin (100 mg) for 30 min at 37°C. The protoplasts were labeled with 100 mCi of [³⁵S]-Promix (Amersham) for 2 minutes and labeling quenched by the addition of 50 ml chase solution. For sedimentation analysis, pulse-labeled staphylococci were centrifuged at 15,000 xg for 10 min to separate soluble surface protein from those that were bound to protoplasts. All samples were precipitated with TCA, washed in acetone and suspended in 50 ml 4% SDS, 0.5 M Tris-HCl pH 7.5 with boiling for 10 min. Aliquots of solubilized surface protein precursor and anchored products were immunoprecipitated with a-Seb and a-BlaZ, subjected to SDS-PAGE and PhosphorImager analysis.

EXAMPLE 3

Purification and Characterization of Sortase-Transpeptidase

To examine whether staphylococcal sortase captures surface proteins after their cleavage at the LPXTG motif as acyl-enzyme intermediates, the proposed acyl-enzyme intermediates between surface protein and sortase were treated by hydroxylaminolysis (P. Lawrence and J. L. Strominger, *J. Biol. Chem.* **245**, 3653 (1970); J. W. Kozarich, N. Tokuzo, E. Willoughby, J. L. Strominger, *J. Biol. Chem.* **252**, 7525 (1977)). In this model, the sulfhydryl of sortase may function as a nucleophile at the peptide bond between threonine and glycine, thereby forming a thioester with the carboxyl of threonine and releasing the amino of glycine (Figure 8A). Lipmann first used hydroxylamine to demonstrate the existence of acyl-enzyme intermediates as this strong nucleophile attacks thioester to form hydroxamate with carboxyl, thereby regenerating enzyme sulfhydryl (F. Lipmann and L. C. Tuttle, *J. Biol. Chem.* **161**, 415 (1945)).

Hydroxylaminolysis of Surface Proteins

Hydroxylaminolysis of surface proteins was examined by pulse-labeling staphylococci with [^{35}S]methionine in either the presence or absence of 0.2 M NH_2OH . Cultures were labeled with [^{35}S]methionine and divided into two aliquots, each of which was precipitated with 5% TCA. One sample was boiled in hot SDS, whereas the other was first treated with lysostaphin to release all anchored surface protein, and then boiled in hot SDS. Surface protein (SEB-SPA490-524) of mock treated staphylococci was insoluble in hot SDS (3.8%) unless the peptidoglycan had been digested with lysostaphin prior to boiling in SDS (100%)(Figure 12A). Addition of 0.2 M NH_2OH caused 25.3% of all labeled SEB-SPA490-524 to be released into the extra-cellular medium and to be soluble in hot SDS. This phenomenon was not strain specific as *S. aureus* OS2 and *S. aureus* BB270 displayed similar amounts of surface protein hydroxylaminolysis.

If the solubility of surface proteins in hot SDS is caused by hydroxylaminolysis of acyl-enzyme intermediates, addition of NH_2OH after the pulse labeling of staphylococci should not release SEB-SPA490-524 as this polypeptide is rapidly anchored to the cell wall. Addition of NH_2OH either before or during the pulse with [^{35}S]methionine released surface proteins into the extra-cellular medium (16.9% and 12.7%, respectively) (Figure 12B). Very little SDS-soluble SEB-SPA490-524 was detected when NH_2OH was added after the pulse (4%). Increasing the amount of NH_2OH prior to pulse-labeling resulted in increased amounts of released surface proteins (Figure 12C).

Characterization of NH_2OH -released Surface Proteins

Hydroxylaminolysis of sortase acyl-intermediates should result in the formation of surface protein hydroxamate at the threonine of the LPXTG motif. To characterize NH_2OH -released surface protein, staphylococci (10^{13} cfu) expressing the surface protein SEB-MH6-CWS (H. Ton-That, K. F. Faull, O. Schneewind, *J. Biol. Chem.* **272**, 22285 (1997)) were incubated in the presence or absence of 0.1 M NH_2OH . Samples were centrifuged to sediment bacteria and SEB-MH6-CWS was purified from the supernatant by affinity chromatography and analyzed on Coomassie-stained SDS-PAGE. Treatment with 0.1 M NH_2OH caused the release of SEB-MH6-CWS by *S. aureus* strains OS2 and BB270 (Figure 13A). SEB-MH6-CWS purified from strain BB270 was cleaved at methionine with cyanogen bromide. COOH-terminal peptides bearing anchor structures were purified by affinity chromatography and analyzed by rpHPLC (H. Ton-That, K. F. Faull, O. Schneewind, *J. Biol. Chem.* **272**, 22285 (1997)). The chromatogram of anchor peptides released from mock treated bacteria revealed a major absorbance peak at 29% CH_3CN (Figure 13B). The sample was subjected to electrospray-ionization mass spectrometry (ESI-MS) and a compound with an average mass of 2236 Da was detected. This measurement is consistent with the structure of anchor peptide linked to a branched cell wall tetrapeptide [L-Ala-D-iGln-L-Lys(NH_2 -H₆AQALPET-Gly₅)-D-Ala,

predicted mass 2235]. This surface protein species is not linked to the glycan strands of the staphylococcal cell wall and is therefore released into the culture medium. The chromatogram of anchor peptides released by treatment with 0.1 M NH₂OH revealed a major absorbance peak at 32% CH₃CN (Figure 13C). ESI-MS identified a compound with the average mass of 1548 Da.

5 When subjected to Edman degradation, the peptide sequence NH₂-H₆AQALPET* was obtained, in which the thirteenth cleavage cycle released a phenylthiohydantoin moiety of unknown structure. The predicted mass of NH₂-H₆AQALPET> (T> indicates threonine hydroxamate) is 1565 Da, 17 Da more than the observed mass of 1548 Da. Fractions of both chromatograms were scanned by rpHPLC for the presence of ion signals with an average mass of 1548, 1565 or
10 2236. rpHPLC fractions of anchor peptides from mock-treated cultures contained the compound with mass 2236, however no ions of the predicted mass 1548 or 1565 were detected. In contrast, rpHPLC fractions collected from anchor peptides of NH₂OH-treated staphylococci harbored compounds with an average mass of 1548 Da (NH₂-H₆AQALPET*, 32% CH₃CN) and 1565 Da (NH₂-H₆AQALPET>, 31% CH₃CN), but not the anchor peptide of 2235 Da. Thus, treatment
15 with 0.1 M NH₂OH released surface protein from staphylococci as a hydroxamate of the threonine within the LPXTG motif, suggesting that sortase forms an acyl-enzyme intermediate with cleaved surface protein. The peptide NH₂-H₆AQALPET> appears to be unstable during our purification, thereby generating NH₂-H₆AQALPET* with a loss of 17 Da at the threonine hydroxamate.

20

Analysis of Sortase Hydroxylaminolysis Activity *In Vitro* in the Presence of NH₂OH

If NH₂OH can release surface protein from staphylococci *in vivo*, sortase may catalyze the cleavage of LPXTG motif bearing peptides in the presence of NH₂OH *in vitro*. Fluorescence of the EDANS fluorophore within the peptide DABCYL-QALPETGEE-EDANS is
25 quenched by the close proximity of DABCYL (G. T. Wang, E. Matayoshi, H. J. Huffaker, G. A. Krafft, *Tetrahedron Lett.* **31**, 6493 (1990)). When the peptide is cleaved and the fluorophore separated from DABCYL, an increase in fluorescence is observed (E. D. Matayoshi, G. T. Wang,

G. A. Krafft, J. Erickson, *Science* **247**, 954 (1989)). Incubation of the LPXTG peptide with crude staphylococcal extracts caused only a small increase in fluorescence. However, the addition of 0.1 M NH₂OH to staphylococcal extracts resulted in a forty fold increase in fluorescence intensity (Figure 14). This activity appears to be specific for sortase as it can be inhibited by pre-incubation of staphylococcal extracts with methanethiosulfonate (MTSET) (D. J. Smith, E. T. Maggio, G. L. Kenyon, *Biochemistry* **14**, 764 (1975), a known inhibitor of the sorting reaction. These results suggest that sortase catalyzes the hydroxylaminolysis of LPXTG peptide *in vitro*. Thus, surface protein is cleaved between the threonine and the glycine of the LPXTG motif, resulting in the formation of a NH₂OH-sensitive thioester linkage between the carboxyl of threonine and the active site sulfhydryl of sortase. *In vivo*, the acyl-enzyme intermediate is resolved by a nucleophilic attack of the amino within the pentaglycine crossbridge. Recent observations suggest that the pentaglycine crossbridge of the lipid II precursor functions as a nucleophile for the sorting reaction. We show here that hydroxylamine can substitute for pentaglycine both *in vivo* and *in vitro*.

Purification and Characterization of Sortase

When expressed in *E. coli* and analyzed by centrifugation of crude lysates, the staphylococcal SrtA protein sedimented with membranes. To obtain a soluble enzyme and to examine its properties, the NH₂-terminal membrane anchor segment of SrtA was replaced with a six histidine tag (SrtADN). SrtADN was expressed in *E. coli* XL-1Blue and purified by affinity chromatography from cleared lysates. When incubated with the LPXTG peptide and measured as an increase in fluorescence, SrtADN catalyzed cleavage of the substrate. Addition of 0.2 M NH₂OH to this reaction resulted in an increase in fluorescence, indicating that cleavage of the LPXTG peptide occurred more efficiently. Hydroxylaminolysis of LPXTG peptide was dependent on the sulfhydryl of SrtADN as pre-incubation with MTSET abolished all enzymatic activity. Methanethiosulfonate forms disulfide with sulfhydryl (D. J. Smith, E. T. Maggio, G. L. Kenyon, *Biochemistry* **14**, 764 (1975); M. H. Akabas and A. Karlin, *Biochemistry* **34**, 12496

(1995)) which can be reversed by reducing reagents such as dithiothreitol (DTT) (R. Pathak, T. L. Hendrickson, B. Imperiali, *Biochemistry* **34**, 4179 (1995)). MTSET-inactivated SrtADN was incubated in the presence of 10 mM DTT, which restored 80% of LPXTG peptide cleavage activity. The availability of purified, soluble sortase (SrtADN) and an *in vitro* assay for the hydroxylaminolysis of LPXTG peptide should allow the screening for compounds that interfere with the anchoring of surface protein in Gram-positive bacteria. Such compounds may be useful for the therapy of human infections with Gram-positive bacteria that have gained resistance to all known antibiotics.

Materials and Methods

Pulse-Chase Screen of Hydroxylaminolysis of surface proteins

Staphylococci were grown in minimal medium until OD₆₀₀ 0.6 and pulse-labeled with 100 μ Ci Pro-Mix ($[^{35}\text{S}]$ methionine and cysteine) for 1 min. Incorporation of radio-label into polypeptides was quenched by the addition of 50 μ l chase solution (100 mg/ml casamino acids, 20 mg/ml methionine and cysteine) and incubation was continued at 37°C for 5 min. Two 0.5 ml aliquots of labeled culture were each precipitated with 0.5 ml 10% TCA, washed in acetone and dried under vacuum. One sample was suspended in 50 μ l 0.5 M Tris, 4% SDS and boiled. The other sample was first suspended in 1 ml 0.5 M Tris pH 7.0 and the cell wall digested for 1 hour at 37°C by adding 50 μ l 2 mg/ml lysostaphin. The sample was precipitated with 75 μ l 100% TCA, washed in acetone, dried and then boiled in SDS. Aliquots were subjected to immunoprecipitation with α -SEB and analyzed after SDS-PAGE on PhosphorImager.

Purification of NH₂OH Surface Proteins

Staphylococci (10^{13} cells) were incubated in 200 ml 50 mM Tris-HCl, pH 7.0 with or without 0.1 M NH₂OH for 60 min. Samples were centrifuged at 10,000 \times g for 15 min and the supernatants applied to 1 ml Ni-NTA column, pre-equilibrated with column buffer (CB, 50 mM Tris-HCl, 150 mM NaCl, pH 7.5). The column was washed first with 20 ml CB and 20

ml CB containing 10% glycerol and eluted with 4 ml of column buffer and 0.5 imidazol. Aliquots were mixed with sample buffer and separated on SDS-PAGE. The eluate was precipitated with TFA (10%), washed in acetone and dried under vacuum. The sample was suspended in 600 µl 70% formic acid and, after addition of a crystal of cyanogen bromide, incubated overnight. Cleaved peptides were repeatedly dried and suspended in water to evaporate cyanogen bromide, solubilized in 1 ml buffer A and subjected to affinity chromatography as previously described. Peptides were eluted in 4 ml of 6 M guanidine-hydrochloride, 0.2 M acetic acid, desalted over C18 cartridge and dried. Pellets were solubilized in 50 µl buffer B (8 M urea, 50 mM phosphate, 10 mM Tris-HCl, pH 7.3) and subjected to rpHPLC on C18 column (Hypersil, Keystone Scientific) with a linear gradient from 1%-99% CH₃CN in 0.1% TFA in 90 minutes. MALDI-MS and ESI-MS was performed as described (H. Ton-That, K.F. Faull, O. Schneewind (1997) *J. Biol. Chem.* 272:22285-22292).

Identification of peptide structure by Mass Spectrometry

The structure of the peptides with mass 1548 and 1565 was determined by tandem mass spectrometry, MS/MS using the parent ions. Collisionally induced dissociation of the parent ions produced daughter ion spectra consistent with compound structures NH₂-H₆AQALPET> (T> is threonine hydroxamate, predicted compound mass 1565) and NH₂-H₆AQALPET* (T* represents a loss of 17 Da of threonine hydroxamate; the structure of this residue is unknown).

Assay of Sortase activity by Fluorescent Assay

Reactions were assembled in a volume of 120 µl containing 50 mM Tris-HCl, 150 mM NaCl, pH 7.5. The concentration of LPXTG peptide substrate (DABCYL-QALPETGEE-EDANS) was 10 µM, of MTSET 5 mM, of NH₂OH 0.2 M. Staphylococcal cell extracts were obtained by subjecting 1013 cells to disruption in a bead beater instrument. The crude extract was subjected to slow speed centrifugation at 3,000 xg for 15 min to remove beads and intact cells. A 10 µl aliquot of the supernatant, containing approximately 50 mg/ml protein, was used

as enzyme preparation. Incubations were carried out for 1 hour at 37°C, followed by centrifugation of the sample at 15,000 xg for 5 min. The supernatant was subjected to analysis in a fluorimeter using 395 nm for excitation and 495 nm for recordings.

5 Purification of Sortase by Addition of Histidine Tag

The primers orf6N-ds-B (5'-AAAGGATCCAAACCACATATCGATAATTATC-3') and orf6C-dT-B (5'-AAAGGATCCTTTGACTTCTGTAGCTACAAAG-3') were used to PCR amplify the *srtA* sequence from the chromosome of *S. aureus* OS2. The DNA fragment was cut with *Bam*HI, inserted into pQE16 (Qiagen) cut *Bam*HI to generate pHTT5, transformed into *E. coli* XL-1 Blue and selected on Luria broth with ampicillin (100 µg/ml). *E. coli* XL-1 Blue (pHTT5) (10¹² cells) were suspended in 30 ml C buffer (50 mM Bis-Tris-HCl, 150 mM NaCl, 10% glycerol, pH 7.2) and lysed by one passage through a French pressure cell at 14,000 psi. The extract was centrifuged at 29,000 xg for 30 min and the supernatant applied to 1 ml Ni-NTA resin, pre-equilibrated with C buffer. The column was washed with 40 ml C buffer and SrtADN protein was eluted in 4 ml C buffer with 0.5 M imidazol at a concentration of 30 µg/µl.

Reactions were assembled in a volume of 260 µl containing 50 mM Hepes buffer, 150 mM NaCl, pH 7.5 and as indicated 5 µM SrtADN in 50 mM BisTris, pH 7.5, 10 µM LPXTG peptide (DABCYL-QALPETGEE-EDANS), 10 µM TGXLP peptide (DABCYL-QATGELPEE-EDANS), 5 mM MTSET, 0.2 M NH₂OH, 5 mM pHMB or 10 mM DTT. Incubations were carried out for 1 hour at 37°C. Samples were analyzed in a fluorimeter using 395 nm for excitation and 495 nm for recordings.

ADVANTAGES OF THE PRESENT INVENTION

In isolating and characterizing the gene for the *S. aureus* sortase-transamidase enzyme, we have determined the existence of a new site for antibiotic action that can be used to screen new antibiotics active against Gram-positive pathogens, such as *Staphylococcus*,
5 *Actinomyces*, *Mycobacterium*, *Streptococcus*, *Bacillus*, and other medically important Gram-positive pathogens increasingly resistant to conventional antibiotics. The availability of substantially purified *S. aureus* sortase-transamidase enzyme provides a method of screening compounds for inhibition of the enzyme.

The purified sortase-transamidase enzyme of the present invention also yields a
10 method of surface display of peptides and proteins that has advantages over phage display, as well as providing methods for producing vaccines against a large variety of antigens that can be covalently bound to the surfaces of Gram-positive bacteria.

Although the present invention has been described with considerable detail, with
reference to certain preferred versions thereof, other versions and embodiments are possible.
15 Therefore, the scope of the invention is determined by the following claims.

TABLE I

Inhibition of the sorting reaction by methanethiosulfonates and organic mercurial

The sorting reaction was measured as the ratio between the amount of pulse-labeled Seb-Spa490-524 P2 precursor [P2] and the mature, anchored species processed at the LPXTG motif [M].

Compound (5 mM)	[P2]/[M]
[2-(trimethylammonium)ethyl]methanethiosulfonate (MTSET)	23.14 ± 0.06 ^a
(2-sulfonatoethyl)methanethiosulfonate (MTSES)	1.61 ± 0.03
p-hydroxymercuribenzoic acid (pHMB)	1.51 ± 0.04
phenylmethylsulfonylfluoride (PMSF)	0.16 ± 0.05
N-ethylmaleimide	0.16 ± 0.05
iodoacetamide	0.12 ± 0.01
iodoacetic acid	0.13 ± 0.02
2-mercaptoethanol	0.15 ± 0.04
dithiothreitol (DTT)	0.13 ± 0.03
zinc chloride (ZnCl ₂)	0.32 ± 0.02
calcium chloride (CaCl ₂)	0.06 ± 0.05
magnesium chloride (MgCl ₂)	0.13 ± 0.01
ethylenediaminetetraacetic acid (EDTA)	0.31 ± 0.04
mock treated	0.15 ± 0.02

^aData represent an average of three measurements. The standard deviation is indicated as ±.

TABLE II

Antibiotic inhibition of cell wall synthesis and the effect on cell wall sorting

The cell wall sorting reaction was measured as the ratio between the amount of pulse-labeled Seb-Cws-BlaZ precursor [P] and the mature, anchored species processed at the LPXTG motif [C]. Cell wall synthesis was measured as the ratio between the amount of [^3H]lysine and that of [^3H]leucine incorporated into the acid precipitable, pronase resistant peptidoglycan. The data are presented as percent inhibition.

Compound	[P2]/[M] ^a	fold inhibition of cell wall synthesis ^a
vancomycin (10 $\mu\text{g/ml}$)	0.47 \pm 0.04	9.5
moenomycin (10 $\mu\text{g/ml}$)	0.24 \pm 0.04	1.6
penicillin (10 $\mu\text{g/ml}$)	0.10 \pm 0.01	3.3
untreated	0.15 \pm 0.02	-

^aData were collected from cultures that were grown for 60 min in the presence of antibiotics.

We claim:

1. A substantially purified sortase-transamidase enzyme from a Gram-positive
5 bacterium, the enzyme catalyzing a reaction that covalently cross-links the carboxyl terminus of
a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, the sorting
signal having a motif of LPX₃X₄G therein, wherein sorting occurs by cleavage between the
fourth and fifth residues of the LPX₃X₄G motif. ✓
- 10 2. The substantially purified sortase-transamidase enzyme of claim 1 wherein the
Gram-positive bacterium is a species selected from the group consisting of *S. aureus*, *S.*
sobrinus, *B. subtilis*, *E. faecalis*, *S. pyogenes*, *S. pneumoniae*, and *L. monocytogenes*.
- 15 3. The substantially purified sortase-transamidase enzyme of claim 2 wherein the
Gram-positive bacterium is *Staphylococcus aureus*.
4. The substantially purified sortase-transamidase enzyme of claim 1 wherein the
enzyme has a molecular weight of about 23,539 daltons.
- 20 5. The substantially purified sortase-transamidase enzyme of claim 4 wherein the
sorting signal further comprises: (2) a substantially hydrophobic domain of at least 31 amino
acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged
residues carboxyl to the substantially hydrophobic domain, at least one of the two positively
charged residues being arginine, the two positively charged residues being located at residues 31-
25 33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is
selected from the group consisting of alanine, serine, and threonine.

6. The enzyme of claim 1 wherein the enzyme includes therein an amino acid sequence selected from the group consisting of : (1) M-K-K-W-T-N-R-L-M-T-I-A-G-V-V-L-I-L-V-A-A-Y-L-F-A-K-P-H-I-D-N-Y-L-H-D-K-D-K-D-E-K-I-E-Q-Y-D-K-N-V-K-E-Q-A-S-K-D-K-K-Q-Q-A-K-P-Q-I-P-K-D-K-S-K-V-A-G-Y-I-E-I-P-D-A-D-I-K-E-P-V-Y-P-G-P-A-T-P-E-Q-L-N-R-G-V-S-F-A-E-E-N-E-S-L-D-D-Q-N-I-S-I-A-G-H-T-F-I-D-R-P-N-Y-Q-F-T-N-L-K-A-A-K-K-G-S-M-V-Y-F-K-V-G-N-E-T-R-K-Y-K-M-T-S-I-R-D-V-K-P-T-D-V-G-V-L-D-E-Q-K-G-K-D-K-Q-L-T-L-I-T-C-D-D-Y-N-E-K-T-G-V-W-E-K-R-K-I-F-V-A-T-E-V-K (SEQ ID NO: 3); and (2) sequences incorporating one or more conservative amino acid substitutions in SEQ ID NO:3, wherein the conservative amino acid substitutions are any of the following: (1) any of isoleucine, leucine, and valine for any other of these amino acids; (2) aspartic acid for glutamic acid and vice versa; (3) glutamine for asparagine and vice versa; and (4) serine for threonine and vice versa.

7. The enzyme of claim 6 wherein the amino acid sequence is M-K-K-W-T-N-R-L-M-T-I-A-G-V-V-L-I-L-V-A-A-Y-L-F-A-K-P-H-I-D-N-Y-L-H-D-K-D-K-D-E-K-I-E-Q-Y-D-K-N-V-K-E-Q-A-S-K-D-K-K-Q-Q-A-K-P-Q-I-P-K-D-K-S-K-V-A-G-Y-I-E-I-P-D-A-D-I-K-E-P-V-Y-P-G-P-A-T-P-E-Q-L-N-R-G-V-S-F-A-E-E-N-E-S-L-D-D-Q-N-I-S-I-A-G-H-T-F-I-D-R-P-N-Y-Q-F-T-N-L-K-A-A-K-K-G-S-M-V-Y-F-K-V-G-N-E-T-R-K-Y-K-M-T-S-I-R-D-V-K-P-T-D-V-G-V-L-D-E-Q-K-G-K-D-K-Q-L-T-L-I-T-C-D-D-Y-N-E-K-T-G-V-W-E-K-R-K-I-F-V-A-T-E-V-K (SEQ ID NO: 3).

8. A nucleic acid sequence encoding the enzyme of claim 6.

9. A nucleic acid sequence encoding the enzyme of claim 7.

10. A nucleic acid sequence encoding a substantially purified sortase-transamidase enzyme from a Gram-positive bacterium, the enzyme having a molecular weight of about 23,539 daltons and catalyzing a reaction that covalently cross-links the carboxyl terminus of a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine, and wherein sorting occurs by cleavage between the fourth and fifth residues of the LPX₃X₄G motif, wherein the nucleic acid sequence includes therein a sequence selected from the group consisting of: (1) ATGAAAAAATGGACAAATCGATTAATGACAATCGCTGGTGTGGTACTTATCCTAGTGGCAGCATATTTGTTTGCTAAACCACATATCGATAATTATCTTCACGATAAAGATAAAGATGATGAAAAGATTGAACAATATGATAAAAATGTAAAAGAACAGGCGAGTAAAGATAAAAAGCAGCAAGCTAAACCTCAAATTCCGAAAGATAAATCGAAAGTGGCAGGCTATATTGAAATTCCAGATGCTGATATTAAAGAACCAGTATATCCAGGACCAGCAACACCTGAACAATTAAATAGAGGTGTAAGCTTTGCAGAAGAAAATGAATCACTAGATGATCAAAATATTTCAATTGCAGGACACACTTTCATTGACCGTCCGAACCTATCAATTTACAAATCTTAAAGCAGCCAAAAAAGGTAGTATGGTGTACTTTAAAGTTGGTAATGAAACACGTAAGTATAAAATGACAAGTATAAGAGATGTTAAGCCTACAGATGTAGGAGTTCTAGATGAACAAAAAGGTAAAGATAAACAATTAACATTAATTACTTGTGATGATTACAAATGAAAAGACAGGCGTTTGGGAAAAACGTAAAATCTTTGTAGCTACAGAAGTCAAATAA (SEQ ID NO: 2); or (2) a sequence complementary to SEQ ID NO: 2.

11. A nucleic acid sequence encoding a substantially purified sortase-
transamidase enzyme from a Gram-positive bacterium, the enzyme having a molecular weight of
about 23,539 daltons and catalyzing a reaction that covalently cross-links the carboxyl terminus
of a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, the
5 sorting signal having (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of
at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two
positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the
two positively charged residues being arginine, the two positively charged residues being located
at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino
10 acids and X₄ is selected from the group consisting of alanine, serine, and threonine, and wherein
sorting occurs by cleavage between the fourth and fifth residues of the LPX₃X₄G motif, wherein
the nucleic acid sequence hybridizes with a sequence selected from the group consisting of: (1)
ATGAAAAAATGGACAAATCGATTAATGACAATCGCTGGTGTGGTACTTATCCTAGTG
GCAGCATATTTGTTTGCTAAACCACATATCGATAATTATCTTCACGATAAAGATAAA
15 GATGAAAAGATTGAACAATATGATAAAAATGTAAAAGAACAGGCGAGTAAAGATA
AAAAGCAGCAAGCTAAACCTCAAATTCCGAAAGATAAATCGAAAGTGGCAGGCTAT
ATTGAAATTCCAGATGCTGATATTAAAGAACCAGTATATCCAGGACCAGCAACACCT
GAACAATTAAATAGAGGTGTAAGCTTTGCAGAAGAAAATGAATCACTAGATGATCA
AAATATTTCAATTGCAGGACACACTTTCATTGACCGTCCGAACCTATCAATTTACAAA
20 TCTTAAAGCAGCCAAAAAAGGTAGTATGGTGTACTTTAAAGTTGGTAATGAAACAC
GTAAGTATAAAATGACAAGTATAAGAGATGTTAAGCCTACAGATGTAGGAGTTCTA
GATGAACAAAAAGGTAAAGATAAACAATTAACATTAATTACTTGTGATGATTACAA
TGAAAAGACAGGCGTTTGGGAAAAACGTAAAATCTTTGTAGCTACAGAAGTCAAAT
AA (SEQ ID NO: 2) or (2) a sequence complementary to SEQ ID NO: 2, with no greater than
25 about a 15% mismatch under stringent conditions.

12. The nucleic acid sequence of claim 11 wherein the mismatch is no greater
than about 5%.

13. The nucleic acid sequence of claim 11 wherein the mismatch is no greater than about 2%.

5 14. A vector comprising the nucleic acid sequence of claim 8 operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence.

10 15. A vector comprising the nucleic acid sequence of claim 9 operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence.

15 16. A vector comprising the nucleic acid sequence of claim 10 operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence.

20 17. A vector comprising the nucleic acid sequence of claim 11 operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence.

18. A host cell transfected with the vector of claim 14.

19. A host cell transfected with the vector of claim 15.

25 20. A host cell transfected with the vector of claim 16.

21. A host cell transfected with the vector of claim 17.

22. A method for producing a substantially purified sortase-transamidase enzyme ✓
comprising the steps of:

(a) culturing the host cell of claim 18 under conditions in which the host cell
expresses the encoded sortase-transamidase enzyme; and

5 (b) purifying the expressed enzyme to produce substantially purified sortase-
transamidase enzyme.

23. A method for producing a substantially purified sortase-transamidase enzyme
comprising the steps of:

10 (a) culturing the host cell of claim 19 under conditions in which the host cell
expresses the encoded sortase-transamidase enzyme; and

(b) purifying the expressed enzyme to produce substantially purified sortase-
transamidase enzyme.

15 24. A method for producing a substantially purified sortase-transamidase enzyme
comprising the steps of:

(a) culturing the host cell of claim 20 under conditions in which the host cell
expresses the encoded sortase-transamidase enzyme; and

20 (b) purifying the expressed enzyme to produce substantially purified sortase-
transamidase enzyme.

25 25. A method for producing a substantially purified sortase-transamidase enzyme
comprising the steps of:

(a) culturing the host cell of claim 21 under conditions in which the host cell
expresses the encoded sortase-transamidase enzyme; and

(b) purifying the expressed enzyme to produce substantially purified sortase-
transamidase enzyme.

26. Substantially purified sortase-transamidase enzyme produced by the process of claim 22.

5 27. Substantially purified sortase-transamidase enzyme produced by the process of claim 23.

28. Substantially purified sortase-transamidase enzyme produced by the process of claim 24.

10 29. Substantially purified sortase-transamidase enzyme produced by the process of claim 25.

30. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of:

- 15 (a) providing the substantially purified sortase-transamidase enzyme of claim 1;
(b) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and
(c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

20 31. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of:

- (a) providing the substantially purified sortase-transamidase enzyme of claim 3;
(b) performing an assay for sortase-transamidase in the presence and in the
25 absence of the compound; and
(c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

32. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of:

(a) providing the substantially purified sortase-transamidase enzyme of claim 26;

5 (b) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

(c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

10 33. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of:

(a) providing the substantially purified sortase-transamidase enzyme of claim 27;

15 (b) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

(c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

20 34. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of:

(a) providing the substantially purified sortase-transamidase enzyme of claim 28;

(b) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

(c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

35. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of:

(a) providing the substantially purified sortase-transamidase enzyme of claim 29;

5 (b) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

(c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

10 36. A method for screening a compound for anti-sortase-transamidase activity comprising the steps of: ✓

(a) providing an active fraction of sortase-transamidase enzyme from a Gram-positive bacterium;

(b) performing an assay for sortase-transamidase in the presence and in the absence of the compound; and

15 (c) comparing the activity of the sortase-transamidase enzyme in the presence and in the absence of the compound to screen the compound for sortase-transamidase activity.

20 37. The method of claim 36 wherein the active fraction of sortase-transamidase enzyme is a particulate fraction from *Staphylococcus aureus*.

38. The method of claim 36 wherein the assay for sortase-transamidase enzyme is performed by monitoring the capture of a soluble peptide that is a substrate for the enzyme by its interaction with an affinity resin.

25 39. The method of claim 38 wherein the soluble peptide includes a sequence of at least six histidine residues and the affinity resin contains nickel.

40. The method of claim 38 wherein the soluble peptide includes the active site of glutathione S-transferase and the affinity resin contains glutathione.

5 41. The method of claim 38 wherein the soluble peptide includes the active site of streptavidin and the affinity resin contains biotin.

42. The method of claim 38 wherein the soluble peptide includes the active site of maltose binding protein and the affinity resin contains amylose.

10 43. An antibody specifically binding the substantially purified sortase-transamidase enzyme of claim 1.

15 44. An antibody specifically binding the substantially purified sortase-transamidase enzyme of claim 3.

20 45. An antibody specifically binding the substantially purified sortase-transamidase enzyme of claim 26.

25 46. An antibody specifically binding the substantially purified sortase-transamidase enzyme of claim 27.

47. An antibody specifically binding the substantially purified sortase-transamidase enzyme of claim 28.

30 48. An antibody specifically binding the substantially purified sortase-transamidase enzyme of claim 29.

49. A protein molecule comprising the substantially purified sortase-transamidase enzyme of claim 1 extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column through the histidine residues added at the carboxyl-terminus.

5

50. A protein molecule comprising the substantially purified sortase-transamidase enzyme of claim 3 extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column through the histidine residues added at the carboxyl-terminus.

10

51. A protein molecule comprising the substantially purified sortase-transamidase enzyme of claim 26 extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column.

15

52. A protein molecule comprising the substantially purified sortase-transamidase enzyme of claim 27 extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column.

20

53. A protein molecule comprising the substantially purified sortase-transamidase enzyme of claim 28 extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column.

25

54. A protein molecule comprising the substantially purified sortase-transamidase enzyme of claim 29 extended at its carboxyl-terminus with a sufficient number of histidine residues to allow specific binding of the protein molecule to a nickel-sepharose column.

55. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed polypeptide; (ii) the substantially purified sortase-transamidase of claim 1; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(c) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4 motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

56. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed polypeptide; (ii) the substantially purified sortase-transamidase of claim 3; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(c) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

57. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed polypeptide; (ii) the substantially purified sortase-transamidase enzyme of claim 26; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(c) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

58. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed polypeptide; (ii) the substantially purified sortase-transamidase enzyme of claim 27; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(c) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

59. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed polypeptide; (ii) the substantially purified sortase-transamidase enzyme of claim 28; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(c) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

60. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) expressing a polypeptide having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed polypeptide; (ii) the substantially purified sortase-transamidase enzyme of claim 29; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide; and

(c) allowing the sortase-transamidase to catalyze a reaction that cleaves the polypeptide within the LPX_3X_4G motif of the sorting signal and covalently cross-links the amino-terminal portion of the cleaved polypeptide to the peptidoglycan to display the polypeptide on the surface of the Gram-positive bacterium.

61. A method for displaying a polypeptide on the surface of a Gram-positive bacterium comprising the steps of:

(a) cloning a nucleic acid segment encoding a chimeric protein into a Gram-positive bacterium to generate a cloned chimeric protein including therein a carboxyl-terminal sorting signal, the chimeric protein including the polypeptide to be displayed, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) growing the bacterium into which the nucleic acid segment has been cloned to express the cloned chimeric protein to generate a chimeric protein including therein a carboxyl-terminal sorting signal; and

(c) binding the polypeptide covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX_3X_4G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand.

62. A polypeptide displayed on the surface of a Gram-positive bacterium by covalent linkage of an amino-acid sequence of LPX_3X_4 derived from cleavage of an LPX_3X_4G motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine, the polypeptide being displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand.

63. A covalent complex comprising:

- (a) the polypeptide of claim 62; and
- (b) an antigen or hapten covalently cross-linked to the polypeptide.

5 64. The covalent complex of claim 63 wherein an antigen is covalently cross-linked to the polypeptide.

65. The covalent complex of claim 63 wherein a hapten is covalently cross-linked to the peptide.

10

66. A method for vaccination of an animal comprising the step of immunizing the animal with the displayed polypeptide of claim 62 to generate an immune response against the displayed polypeptide.

15

67. A method for vaccination of an animal comprising the step of immunizing the animal with the covalent complex of claim 63 to generate an immune response against the antigen or hapten of the covalent complex.

68. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed chimeric protein; the substantially purified sortase-transamidase enzyme of claim 1; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;

(c) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

69. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) the substantially purified sortase-transamidase enzyme of claim 3; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;

(c) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

70. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) the substantially purified sortase-transamidase enzyme of claim 26; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;

(c) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

71. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) the substantially purified sortase-transamidase enzyme of claim 27; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;

(c) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

72. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) the substantially purified sortase-transamidase enzyme of claim 28; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;

(c) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

73. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) expressing a cloned polypeptide as a chimeric protein having a sorting signal at its carboxy-terminal end, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine;

(b) forming a reaction mixture including: (i) the expressed chimeric protein; (ii) the substantially purified sortase-transamidase enzyme of claim 29; and (iii) a Gram-positive bacterium having a peptidoglycan to which the sortase-transamidase can link the polypeptide through the sorting signal;

(c) binding the chimeric protein covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX₃X₄G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

74. A method for screening for expression of a cloned polypeptide comprising the steps of:

(a) cloning a nucleic acid segment encoding a chimeric protein into a Gram-positive bacterium to generate a cloned chimeric protein including therein a carboxyl-terminal sorting signal, the chimeric protein including the polypeptide whose expression is to be screened, the sorting signal having: (1) a motif of LPX_3X_4G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X_3 is any of the twenty naturally-occurring L-amino acids and X_4 is selected from the group consisting of alanine, serine, and threonine;

(b) growing the bacterium into which the nucleic acid segment has been cloned to express the cloned chimeric protein to generate a chimeric protein including therein a carboxyl-terminal sorting signal;

(c) binding the polypeptide covalently to the cell wall by the enzymatic action of a sortase-transamidase expressed by the Gram-positive bacterium involving cleavage of the chimeric protein within the LPX_3X_4G motif so that the polypeptide is displayed on the surface of the Gram-positive bacterium in such a way that the polypeptide is accessible to a ligand; and

(d) reacting the displayed polypeptide with a labeled specific binding partner to screen the chimeric protein for reactivity with the labeled specific binding partner.

75. A method for the diagnosis or treatment of a bacterial infection caused by a Gram-positive bacterium comprising the steps of:

(a) conjugating an antibiotic or a detection reagent to a protein including therein a carboxyl-terminal sorting signal to produce a conjugate, the carboxyl-terminal sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine; and

(b) introducing the conjugate to an organism infected with a Gram-positive bacterium in order to cause the conjugate to be sorted and covalently cross-linked to the cell walls of the bacterium in order to treat or diagnose the infection.

76. The method of claim 75 wherein an antibiotic is conjugated to the protein.

77. The method of claim 76 wherein the antibiotic is selected from the group consisting of a penicillin, ampicillin, vancomycin, gentamicin, streptomycin, a cephalosporin, amikacin, kanamycin, neomycin, paromomycin, tobramycin, ciprofloxacin, clindamycin, rifampin, chloramphenicol, norfloxacin, and a derivative of these antibiotics.

78. The method of claim 75 wherein a detection reagent is conjugated to the protein.

79. A conjugate comprising an antibiotic or a detection reagent covalently conjugated to a protein including therein a carboxyl-terminal sorting signal to produce a conjugate, the carboxyl-terminal sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine.

80. The conjugate of claim 79 wherein an antibiotic is conjugated to the protein.

81. The conjugate of claim 80 wherein the antibiotic is selected from the group consisting of a penicillin, ampicillin, vancomycin, gentamicin, streptomycin, a cephalosporin, amikacin, kanamycin, neomycin, paromomycin, tobramycin, ciprofloxacin, clindamycin, rifampin, chloramphenicol, norfloxacin, and a derivative of these antibiotics.

82. The conjugate of claim 79 wherein a detection reagent is conjugated to the protein.

83. A composition comprising:

- (a) the conjugate of claim 79; and
- (b) a pharmaceutically acceptable carrier.

84. A substantially purified protein having at least about 30% sequence similarity ✓
with the amino acid sequences of at least one of *S. pyogenes* (SEQ ID NO: 4), *A. naeslundii*
(SEQ. ID NO. 5), *E. faecalis* (SEQ. ID NO. 6), *S. mutans* (SEQ. ID NO. 7) *S. pneumoniae*
(SEQ. ID NO. 34, SEQ. ID NO. 35, or SEQ ID NO. 36) or *B. subtilis* (SEQ. ID NO. 8) and
5 having sortase-transamidase activity.

85. The substantially purified protein of claim 84 wherein the sequence similarity
with the amino acid sequences of at least one of *S. pyogenes* (SEQ ID NO: 4), *A. naeslundii*
(SEQ. ID NO. 5), *E. faecalis* (SEQ. ID NO. 6), *S. mutans* (SEQ. ID NO. 7) *S. pneumoniae*
10 (SEQ. ID NO. 34, SEQ. ID NO. 35, or SEQ ID NO. 36) or *B. subtilis* (SEQ. ID NO. 8) is at least
about 40%.

86. The substantially purified protein of claim 85 wherein the sequence similarity
with the amino acid sequences of at least one of *S. pyogenes* (SEQ ID NO: 4), *A. naeslundii*
15 (SEQ. ID NO. 5), *E. faecalis* (SEQ. ID NO. 6), *S. mutans* (SEQ. ID NO. 7) *S. pneumoniae*
(SEQ. ID NO. 34, SEQ. ID NO. 35, or SEQ ID NO. 36) or *B. subtilis* (SEQ. ID NO. 8) is at least
about 50%.

87. A substantially purified protein having at least about 18% sequence identity ✓
20 with the amino acid sequences of at least one of *S. pyogenes* (SEQ ID NO: 4), *A. naeslundii*
(SEQ. ID NO. 5), *E. faecalis* (SEQ. ID NO. 6), *S. mutans* (SEQ. ID NO. 7) *S. pneumoniae*
(SEQ. ID NO. 34, SEQ. ID NO. 35, or SEQ ID NO. 36) or *B. subtilis* (SEQ. ID NO. 8) and
having sortase-transamidase activity.

88. The substantially purified protein of claim 84 wherein the sequence identity
25 with the amino acid sequences of at least one of *S. pyogenes* (SEQ ID NO: 4), *A. naeslundii*
(SEQ. ID NO. 5), *E. faecalis* (SEQ. ID NO. 6), *S. mutans* (SEQ. ID NO. 7) *S. pneumoniae*

(SEQ. ID NO. 34, SEQ. ID NO. 35, or SEQ ID NO. 36) or *B. subtilis* (SEQ. ID NO. 8) is at least about 20%.

89. The substantially purified protein of claim 85 wherein the sequence identity with the amino acid sequences of at least one of *S. pyogenes* (SEQ ID NO: 4), *A. naeshlundii* (SEQ. ID NO. 5), *E. faecalis* (SEQ. ID NO. 6), *S. mutans* (SEQ. ID NO. 7) *S. pneumoniae* (SEQ. ID NO. 34, SEQ. ID NO. 35, or SEQ ID NO. 36) or *B. subtilis* (SEQ. ID NO. 8) is at least about 30%.

90. A nucleic acid sequence encoding the substantially purified protein of claim 84.

91. A vector comprising the nucleic acid sequence of claim 90 operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence.

92. A host cell transfected with the vector of claim 91.

93. A method for producing a substantially purified protein having sortase-transamidase activity comprising the steps of:

(a) culturing the host cell of claim 92 under conditions in which the host cell expresses the protein having sortase-transamidase activity; and

(b) purifying the expressed protein to produce substantially purified protein having sortase-transamidase activity.

94. A nucleic acid sequence encoding the substantially purified protein of claim 87.

95. A vector comprising the nucleic acid sequence of claim 94 operatively linked to at least one control sequence that controls the expression or regulation of the nucleic acid sequence.

5

96. A host cell transfected with the vector of claim 95.

97. A method for producing a substantially purified protein having sortase-transamidase activity comprising the steps of:

10 (a) culturing the host cell of claim 96 under conditions in which the host cell expresses the protein having sortase-transamidase activity; and

(b) purifying the expressed protein to produce substantially purified protein having sortase-transamidase activity.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188

ABSTRACT

The present invention is a substantially purified sortase-transamidase enzyme from Gram-positive bacteria, such as *Staphylococcus aureus*. The enzyme having a molecular weight of about 23,539 daltons and catalyzing a reaction that covalently cross-links the carboxyl terminus of a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, the sorting signal having: (1) a motif of LPX₃X₄G therein; (2) a substantially hydrophobic domain of at least 31 amino acids carboxyl to the motif; and (3) a charged tail region with at least two positively charged residues carboxyl to the substantially hydrophobic domain, at least one of the two positively charged residues being arginine, the two positively charged residues being located at residues 31-33 from the motif, wherein X₃ is any of the twenty naturally-occurring L-amino acids and X₄ is selected from the group consisting of alanine, serine, and threonine, and wherein sorting occurs by cleavage between the fourth and fifth residues of the LPX₃X₄G motif. Variants of the enzyme, methods for cloning the gene encoding the enzyme and expressing the cloned gene, and methods of use of the enzyme, including for screening for antibiotics and for display of proteins or peptides on the surfaces of Gram-positive bacteria, are also disclosed.

FIGURE 1




FIGURE 2







FIGURE 3




Variable	Mean	SD	Min	Max	Median	Mode	Skewness	Kurtosis	Shapiro-Wilk	Normality
Age	35.2	12.5	18	65	32	30	0.15	2.8	0.98	Normal
Gender	1.2	0.4	1	2	1	1	0.05	1.2	0.99	Normal
Marital Status	1.5	0.5	1	3	1	1	0.10	1.5	0.97	Normal
Education	12.5	2.0	8	16	12	12	0.08	2.5	0.99	Normal
Income	1500	500	500	3000	1200	1000	0.20	3.0	0.95	Normal
Occupation	1.8	0.6	1	3	1	1	0.05	1.2	0.99	Normal
Health Status	1.2	0.4	1	2	1	1	0.05	1.2	0.99	Normal
Stress Level	2.5	0.8	1	4	2	2	0.10	1.5	0.97	Normal
Life Satisfaction	3.5	1.0	1	5	3	3	0.05	1.2	0.99	Normal
Work-Life Balance	2.0	0.7	1	3	2	2	0.10	1.5	0.97	Normal
Family Support	1.5	0.5	1	3	1	1	0.05	1.2	0.99	Normal
Community Involvement	1.0	0.3	0	2	1	1	0.05	1.2	0.99	Normal
Personal Growth	2.0	0.8	1	4	2	2	0.10	1.5	0.97	Normal
Overall Well-being	3.0	1.0	1	5	3	3	0.05	1.2	0.99	Normal



B



C






FIG. 5

[illegible]

206

FIGURE 7

		1	15	30	45	60	75	90	
1	Anei	-----	MGLLTYP	TAASWVSQYNQSKVTADYSAQVDG	---ARPD	AKTQVEQAHAYND	-ALSAGAVLEANNHYPTG	65	
2	Spyo	-----	-----	-----	-----	MEEVWQAKAYNA	-RLGIOVPVDAFS	29	
3	Efea	MKSKKKRIIDGFMILLIIGIGAFAYPFVSDALNNYLDQOI	IAHYQAKASOE	---NTKEMAELOEKMEKKNO	-ELAKKGSNPG	LDPESET	87		
4	Bsub	-----	-----	MKKVIFLPIIAAGLVIAGYG	-GFKLIDTNTKTEOTLKE	-AKLAAKKPOEASG	TKNS	54	
5	Smut	-----	-----	MKKERQSRKRSFLR	TFLPILLIIGLALIFNTPIRNALIAWNTNRYQVSNVSKKDI	EHNKAAHSSDFK	70		
6	Saur	-----	-----	MKKWTNRNLM	TAGVVLILV	-AAYLFAKPHIDN	YLDV-KDKDEKIEQYDKNQVKEQ	52	
1	Anei	AGSSKDSSLOYANILKANNEGIMAREKMT	PSISLDL	IVYHG	-TADDT	LLALCHLEGTSL	EVGEGTRSVITG	151	
2	Spyo	IHD-KN	---YESL	QIENNDIMGVEM	PSIKVTL	IIYH	-TDEVT	110	
3	Efea	QKTTKKP	---DKSYFESHT	---IGVLT	PKINVR	LEFDK	-TNALL	167	
4	Bsub	TQAKN	---KASFKPETG	-OASGILE	PKINAE	LIVEG	-TDADD	129	
5	Smut	KVEST	STQSVLAAQMAAQKLPVIGGTAS	EDLKINE	PIFKG	-LDNVGL	TYAGTMKNDVHG	157	
6	Saur	ASKDKKQQ	---AKPQIPKDKSKVAGYTE	EDDADIK	EVYFGPATPEQ	NR	VSFAENESLD	135	
1	Anei	VKTE	DSLIVEVFGVLT	IRVTSTKV	EEETEAL	VEEGKDL	-LIVVCTPI	237	
2	Spyo	VKK	EDTFYFRVLNKVLAKVDQELT	VEDQVTSLSGVMGDI	-AVVCTPY	---GVNTR	KLIRGHRIAXHYKKYQOAKKAMKLVKSR	196	
3	Efea	LKK	DEFEYIEVNGKELANQVDQIKT	VEEDTKDLHIESGQDL	-VTLVCTPY	---MINSER	LLVRGHRIFYOPEKAAAGMKKVAQQNLL	253	
4	Bsub	LEK	EDQLRLLSYGEFTHEIVKTKI	DDKDDTSTITLOHEKEE	-LILFIC	YFFSYVGNAPKRYTYGKRV	---	198	
5	Smut	AKP	MEIYLTDKNKVYTHVISEVKT	VEHVEN	DNRPQNE	-VTLVCTDA	---GATARTVHGTYKGENDFNKTSKKIKAFROSYN	242	
6	Saur	AKI	SMYFEKGNETREKMTSIRDK	KPTLVGV	LEQKSGDKQ	TLVCTDY	---NEK	206	
1	Anei	WWAVGLAAGLIVVGLYLWRSGYAAARAKERALARARAAQEEPQ	PQTWAEQ	MRIMDDAGVEPQRWFTDLVPVPQ	QPMENLALLEEIAS	---	---	327	
2	Spyo	MMAEVVCAAFGVVIAIILVFMYSRVS	SAKSK	---	---	---	---	227	
3	Efea	LWTLILLIACALIISGFIIWYKRRKKTTRKPK	---	---	---	---	---	284	
4	Bsub	---	---	---	---	---	---	198	
5	Smut	QISF	---	---	---	---	---	246	
6	Saur	---	---	---	---	---	---	206	
1	Anei	LSAPSGRWDDQELIDTA	EIPVL	DATRPSAGTSGRTHRL	365	(SEQ. ID NO. 5)			
2	Spyo	---	---	---	227	(SEQ. ID NO. 4)			
3	Efea	---	---	---	284	(SEQ. ID NO. 6)			
4	Bsub	---	---	---	198	(SEQ. ID NO. 8)			
5	Smut	---	---	---	246	(SEQ. ID NO. 7)			
6	Saur	---	---	---	206	(SEQ. ID NO. 3)			

FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13









FIGURE 14



United States Patent Application

DECLARATION

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: IDENTIFICATION OF SORTASE GENE

The specification of which

a. ☒ is attached hereto

b. ☐ was filed on _____ as application serial no. _____ and was amended on _____ (if applicable) (in the case of a PCT-filed application) described and claimed in international no. _____ filed _____ and as amended on _____ (if any), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

a. ☒ no such applications have been filed.

b. ☐ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
ALL FOREIGN APPLICATION(S), IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

U.S. PROVISIONAL APPLICATION NUMBER	DATE OF FILING (Day, Month, Year)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

201	Full Name Of Inventor	Family Name Schneewind	First Given Name Olaf	Second Given Name
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship Germany
	Post Office Address	Post Office Address 11050 Strathmore Drive, #422	City Los Angeles	State & Zip Code/Country California 90024 USA
Signature of Inventor 201:			Date:	
202	Full Name Of Inventor	Family Name Mazmanian	First Given Name Sarkis	Second Given Name
	Residence & Citizenship	City Sherman Oaks	State or Foreign Country California	Country of Citizenship U.S.A.
	Post Office Address	Post Office Address 4401 North Sepulveda Boulevard, #310	City Sherman Oaks	State & Zip Code/Country California 91403 USA
Signature of Inventor 202:			Date:	
203	Full Name Of Inventor	Family Name Liu	First Given Name Gwen	Second Given Name
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship U.S.A.
	Post Office Address	Post Office Address 11611 Chenault Street, #203	City Los Angeles	State & Zip Code/Country California 90049 USA
Signature of Inventor 203:			Date:	
204	Full Name Of Inventor	Family Name Ton-That	First Given Name Hung	Second Given Name
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship Vietnam
	Post Office Address	Post Office Address 6021 Piedmont Avenue	City Los Angeles	State & Zip Code/Country California 90042 USA
Signature of Inventor 204:			Date:	

§ 1.56 'Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

(1) prior art cited in search reports of a foreign patent office in a counterpart application, and

(2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim;

or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

(i) Opposing an argument of unpatentability relied on by the Office, or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) Each inventor named in the application:

(2) Each attorney or agent who prepares or prosecutes the application; and

(3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

SEQUENCE LISTING

<110> Olaf Schneewind
Sarkis Mazmanian
Gwen Liu
Hung Ton-That

<120> IDENTIFICATION OF SORTASE GENE

<130> 510015.213

<160> 36

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 5

<212> PRT

<213> Bacteria

<400> 1

Leu Pro Xaa Thr Gly
1 5

<210> 2

<211> 621

<212> DNA

<213> Staphylococcus aureus

<220>

<221> CDS

<222> (1)...(621)

<400> 2

atg	aaa	aaa	tgg	aca	aat	cga	tta	atg	aca	atc	gct	ggg	gtg	gta	ctt	48
Met	Lys	Lys	Trp	Thr	Asn	Arg	Leu	Met	Thr	Ile	Ala	Gly	Val	Val	Leu	
1				5					10					15		

atc	cta	gtg	gca	gca	tat	ttg	ttt	gct	aaa	cca	cat	atc	gat	aat	tat	96
Ile	Leu	Val	Ala	Ala	Tyr	Leu	Phe	Ala	Lys	Pro	His	Ile	Asp	Asn	Tyr	
			20					25					30			

ctt	cac	gat	aaa	gat	aaa	gat	gaa	aag	att	gaa	caa	tat	gat	aaa	aat	144
Leu	His	Asp	Lys	Asp	Lys	Asp	Glu	Lys	Ile	Glu	Gln	Tyr	Asp	Lys	Asn	
		35					40					45				

gta	aaa	gaa	cag	gcg	agt	aaa	gat	aaa	aag	cag	caa	gct	aaa	cct	caa	192
Val	Lys	Glu	Gln	Ala	Ser	Lys	Asp	Lys	Lys	Gln	Gln	Ala	Lys	Pro	Gln	
	50					55				60						

att	ccg	aaa	gat	aaa	tcg	aaa	gtg	gca	ggc	tat	att	gaa	att	cca	gat	240
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Ile 65	Pro	Lys	Asp	Lys	Ser 70	Lys	Val	Ala	Gly	Tyr 75	Ile	Glu	Ile	Pro	Asp 80	
gct Ala	gat Asp	att Ile	aaa Lys	gaa Glu	cca Pro	gta Val	tat Tyr	cca Pro	gga Gly	cca Pro	gca Ala	aca Thr	cct Pro	gaa Glu	caa Gln	288
tta Leu	aat Asn	aga Arg	ggt Gly	gta Val	agc Ser	ttt Phe	gca Ala	gaa Glu	gaa Glu	aat Asn	gaa Glu	tca Ser	cta Leu	gat Asp	gat Asp	336
caa Gln	aat Asn	att Ile	tca Ser	att Ile	gca Ala	gga Gly	cac His	act Thr	ttc Phe	att Ile	gac Asp	cgt Arg	ccg Pro	aac Asn	tat Tyr	384
caa Gln	ttt Phe	aca Thr	aat Asn	ctt Leu	aaa Lys	gca Ala	gcc Ala	aaa Lys	aaa Lys	ggt Gly	agt Ser	atg Met	gtg Val	tac Tyr	ttt Phe	432
aaa Lys	ggt Val	ggt Gly	aat Asn	gaa Glu	aca Thr	cgt Arg	aag Lys	tat Tyr	aaa Lys	atg Met	aca Thr	agt Ser	ata Ile	aga Arg	gat Asp	480
ggt Val	aag Lys	cct Pro	aca Thr	gat Asp	gta Val	gga Gly	ggt Val	cta Leu	gat Asp	gaa Glu	caa Gln	aaa Lys	ggt Gly	aaa Lys	gat Asp	528
aaa Lys	caa Gln	tta Leu	aca Thr	tta Leu	att Ile	act Thr	tgt Cys	gat Asp	gat Asp	tac Tyr	aat Asn	gaa Glu	aag Lys	aca Thr	ggc Gly	576
ggt Val	tgg Trp	gaa Glu	aaa Lys	cgt Arg	aaa Lys	atc Ile	ttt Phe	gta Val	gct Ala	aca Thr	gaa Glu	gtc Val	aaa Lys	taa *		621

<210> 3
 <211> 206
 <212> PRT
 <213> Staphylococcus aureus

<400> 3
 Met Lys Lys Trp Thr Asn Arg Leu Met Thr Ile Ala Gly Val Val Leu
 1 5 10 15
 Ile Leu Val Ala Ala Tyr Leu Phe Ala Lys Pro His Ile Asp Asn Tyr
 20 25 30
 Leu His Asp Lys Asp Lys Asp Glu Lys Ile Glu Gln Tyr Asp Lys Asn
 35 40 45
 Val Lys Glu Gln Ala Ser Lys Asp Lys Lys Gln Gln Ala Lys Pro Gln
 50 55 60
 Ile Pro Lys Asp Lys Ser Lys Val Ala Gly Tyr Ile Glu Ile Pro Asp
 65 70 75 80
 Ala Asp Ile Lys Glu Pro Val Tyr Pro Gly Pro Ala Thr Pro Glu Gln

Leu	Asn	Arg	Gly	Val	Ser	Phe	Ala	Glu	Glu	Asn	Glu	Ser	Leu	Asp	Asp
			100					105					110		
Gln	Asn	Ile	Ser	Ile	Ala	Gly	His	Thr	Phe	Ile	Asp	Arg	Pro	Asn	Tyr
		115					120					125			
Gln	Phe	Thr	Asn	Leu	Lys	Ala	Ala	Lys	Lys	Gly	Ser	Met	Val	Tyr	Phe
	130					135					140				
Lys	Val	Gly	Asn	Glu	Thr	Arg	Lys	Tyr	Lys	Met	Thr	Ser	Ile	Arg	Asp
145					150					155					160
Val	Lys	Pro	Thr	Asp	Val	Gly	Val	Leu	Asp	Glu	Gln	Lys	Gly	Lys	Asp
				165					170					175	
Lys	Gln	Leu	Thr	Leu	Ile	Thr	Cys	Asp	Asp	Tyr	Asn	Glu	Lys	Thr	Gly
			180					185					190		
Val	Trp	Glu	Lys	Arg	Lys	Ile	Phe	Val	Ala	Thr	Glu	Val	Lys		
		195					200					205			

<210> 4
 <211> 227
 <212> PRT
 <213> Streptococcus pyogenes

Met	Glu	Glu	Val	Trp	Gln	Lys	Ala	Lys	Ala	Tyr	Asn	Ala	Arg	Leu	Gly
1				5				10						15	
Thr	Gln	Pro	Val	Pro	Asp	Ala	Phe	Ser	Phe	Arg	Asp	Gly	Ile	His	Asp
			20					25					30		
Lys	Asn	Tyr	Glu	Ser	Leu	Leu	Gln	Ile	Glu	Asn	Asn	Asp	Ile	Met	Gly
		35					40					45			
Tyr	Val	Glu	Val	Pro	Ser	Ile	Lys	Val	Thr	Leu	Pro	Ile	Tyr	His	Tyr
	50					55					60				
Thr	Thr	Asp	Glu	Val	Leu	Thr	Lys	Gly	Ala	Gly	His	Leu	Phe	Gly	Ser
65					70					75					80
Ala	Leu	Pro	Val	Gly	Gly	Asp	Gly	Thr	His	Thr	Val	Ile	Ser	Ala	His
				85					90					95	
Arg	Gly	Leu	Pro	Ser	Ala	Glu	Met	Phe	Thr	Asn	Leu	Asn	Leu	Val	Lys
			100					105					110		
Lys	Gly	Asp	Thr	Phe	Tyr	Phe	Arg	Val	Leu	Asn	Lys	Val	Leu	Ala	Tyr
		115					120					125			
Lys	Val	Asp	Gln	Ile	Leu	Thr	Val	Glu	Pro	Asp	Gln	Val	Thr	Ser	Leu
	130					135					140				
Ser	Gly	Val	Met	Gly	Lys	Asp	Tyr	Ala	Thr	Leu	Val	Thr	Cys	Thr	Pro
145					150					155					160
Tyr	Gly	Val	Asn	Thr	Lys	Arg	Leu	Leu	Val	Arg	Gly	His	Arg	Ile	Ala
				165					170					175	
Tyr	His	Tyr	Lys	Lys	Tyr	Gln	Gln	Ala	Lys	Lys	Ala	Met	Lys	Leu	Val
			180					185					190		
Asp	Lys	Ser	Arg	Met	Trp	Ala	Glu	Val	Val	Cys	Ala	Ala	Phe	Gly	Val
		195					200					205			
Val	Ile	Ala	Ile	Ile	Leu	Val	Phe	Met	Tyr	Ser	Arg	Val	Ser	Ala	Lys
	210					215					220				
Lys	Ser	Lys													
225															

<210> 5
 <211> 365
 <212> PRT
 <213> Actinomyces naeslundii

<400> 5

Met	Gly	Leu	Leu	Thr	Tyr	Pro	Thr	Ala	Ala	Ser	Trp	Val	Ser	Gln	Tyr
1				5					10					15	
Asn	Gln	Ser	Lys	Val	Thr	Ala	Asp	Tyr	Ser	Ala	Gln	Val	Asp	Gly	Ala
			20					25					30		
Arg	Pro	Asp	Ala	Lys	Thr	Gln	Val	Glu	Gln	Ala	His	Ala	Tyr	Asn	Asp
		35					40					45			
Ala	Leu	Ser	Ala	Gly	Ala	Val	Leu	Glu	Ala	Asn	Asn	His	Val	Pro	Thr
	50					55					60				
Gly	Ala	Gly	Ser	Ser	Lys	Asp	Ser	Ser	Leu	Gln	Tyr	Ala	Asn	Ile	Leu
65					70					75					80
Lys	Ala	Asn	Asn	Glu	Gly	Leu	Met	Ala	Arg	Leu	Lys	Ile	Pro	Ser	Ile
				85					90					95	
Ser	Leu	Asp	Leu	Pro	Val	Tyr	His	Gly	Thr	Ala	Asp	Asp	Thr	Leu	Leu
			100					105					110		
Lys	Gly	Leu	Gly	His	Leu	Glu	Gly	Thr	Ser	Leu	Pro	Val	Gly	Gly	Glu
		115					120						125		
Gly	Thr	Arg	Ser	Val	Ile	Thr	Gly	His	Arg	Gly	Leu	Ala	Glu	Ala	Thr
	130					135					140				
Met	Phe	Thr	Asn	Leu	Asp	Lys	Val	Lys	Thr	Gly	Asp	Ser	Leu	Ile	Val
145					150					155					160
Glu	Val	Phe	Gly	Glu	Val	Leu	Thr	Tyr	Arg	Val	Thr	Ser	Thr	Lys	Val
				165					170					175	
Val	Glu	Pro	Glu	Glu	Thr	Glu	Ala	Leu	Arg	Val	Glu	Glu	Gly	Lys	Asp
			180					185					190		
Leu	Leu	Thr	Leu	Val	Thr	Cys	Thr	Pro	Leu	Gly	Ile	Asn	Thr	His	Arg
		195					200					205			
Ile	Leu	Leu	Thr	Gly	Glu	Arg	Ile	Tyr	Pro	Thr	Pro	Ala	Lys	Asp	Leu
	210					215					220				
Ala	Ala	Ala	Gly	Lys	Arg	Pro	Asp	Val	Pro	His	Phe	Pro	Trp	Trp	Ala
225					230					235					240
Val	Gly	Leu	Ala	Ala	Gly	Leu	Ile	Val	Val	Gly	Leu	Tyr	Leu	Trp	Arg
				245					250					255	
Ser	Gly	Tyr	Ala	Ala	Ala	Arg	Ala	Lys	Glu	Arg	Ala	Leu	Ala	Arg	Ala
			260					265					270		
Arg	Ala	Ala	Gln	Glu	Glu	Pro	Gln	Pro	Gln	Thr	Trp	Ala	Glu	Gln	Met
		275					280						285		
Arg	Ile	Trp	Met	Asp	Asp	Asp	Ala	Gly	Val	Glu	Pro	Gln	Arg	Trp	Phe
	290				295						300				
Thr	Asp	Leu	Pro	Val	Pro	Pro	Gln	Pro	Ser	Glu	Met	Glu	Asn	Leu	Ala
305					310					315					320
Leu	Leu	Glu	Glu	Ile	Ala	Ser	Leu	Ser	Ala	Pro	Ser	Gly	Arg	Trp	Asp
				325					330					335	
Asp	Gln	Glu	Leu	Ile	Asp	Thr	Ala	Glu	Ile	Pro	Val	Leu	Asp	Ala	Thr
			340					345					350		
Arg	Pro	Ser	Ala	Gly	Thr	Ser	Gly	Arg	Thr	His	Arg	Leu			
		355					360					365			

<210> 6
 <211> 284
 <212> PRT
 <213> Enterococcus faecalis

<400> 6

Met	Lys	Ser	Lys	Lys	Lys	Arg	Arg	Ile	Ile	Asp	Gly	Phe	Met	Ile	Leu	
1				5					10					15		
Leu	Leu	Ile	Ile	Gly	Ile	Gly	Ala	Phe	Ala	Tyr	Pro	Phe	Val	Ser	Asp	
			20				25						30			
Ala	Leu	Asn	Asn	Tyr	Leu	Asp	Gln	Gln	Ile	Ile	Ala	His	Tyr	Gln	Ala	
		35				40						45				
Lys	Ala	Ser	Gln	Glu	Asn	Thr	Lys	Glu	Met	Ala	Glu	Leu	Gln	Glu	Lys	
	50					55					60					
Met	Glu	Lys	Lys	Asn	Gln	Glu	Leu	Ala	Lys	Lys	Gly	Ser	Asn	Pro	Gly	
65				70					75						80	
Leu	Asp	Pro	Phe	Ser	Glu	Thr	Gln	Lys	Thr	Thr	Lys	Lys	Pro	Asp	Lys	
				85					90					95		
Ser	Tyr	Phe	Glu	Ser	His	Thr	Ile	Gly	Val	Leu	Thr	Ile	Pro	Lys	Ile	
			100					105					110			
Asn	Val	Arg	Leu	Pro	Ile	Phe	Asp	Lys	Thr	Asn	Ala	Leu	Leu	Leu	Glu	
		115					120					125				
Lys	Gly	Ser	Ser	Leu	Leu	Glu	Gly	Thr	Ser	Tyr	Pro	Thr	Gly	Gly	Thr	
	130					135					140					
Asn	Thr	His	Ala	Val	Ile	Ser	Gly	His	Arg	Gly	Leu	Pro	Gln	Ala	Lys	
145					150					155					160	
Leu	Phe	Thr	Asp	Leu	Pro	Glu	Leu	Lys	Lys	Gly	Asp	Glu	Phe	Tyr	Ile	
				165				170						175		
Glu	Val	Asn	Gly	Lys	Thr	Leu	Ala	Tyr	Gln	Val	Asp	Gln	Ile	Lys	Thr	
			180					185					190			
Val	Glu	Pro	Thr	Asp	Thr	Lys	Asp	Leu	His	Ile	Glu	Ser	Gly	Gln	Asp	
		195					200					205				
Leu	Val	Thr	Leu	Leu	Thr	Cys	Thr	Pro	Tyr	Met	Ile	Asn	Ser	His	Arg	
	210					215					220					
Leu	Leu	Val	Arg	Gly	His	Arg	Ile	Pro	Tyr	Gln	Pro	Glu	Lys	Ala	Ala	
225					230					235					240	
Ala	Gly	Met	Lys	Lys	Val	Ala	Gln	Gln	Gln	Asn	Leu	Leu	Leu	Trp	Thr	
				245				250						255		
Leu	Leu	Leu	Ile	Ala	Cys	Ala	Leu	Ile	Ile	Ser	Gly	Phe	Ile	Ile	Trp	
			260					265					270			
Tyr	Lys	Arg	Arg	Lys	Lys	Thr	Thr	Arg	Lys	Pro	Lys					
		275					280									

<210> 7
 <211> 246
 <212> PRT
 <213> Streptococcus mutans

<400> 7

Met	Lys	Lys	Glu	Arg	Gln	Ser	Arg	Lys	Lys	Arg	Ser	Phe	Leu	Arg	Thr	
1				5					10					15		
Phe	Leu	Pro	Ile	Leu	Leu	Leu	Val	Ile	Gly	Leu	Ala	Leu	Ile	Phe	Asn	
			20					25					30			

Thr	Pro	Ile	Arg	Asn	Ala	Leu	Ile	Ala	Trp	Asn	Thr	Asn	Arg	Tyr	Gln
		35					40					45			
Val	Ser	Asn	Val	Ser	Lys	Lys	Asp	Ile	Glu	His	Asn	Lys	Ala	Ala	His
	50				55						60				
Ser	Ser	Phe	Asp	Phe	Lys	Lys	Val	Glu	Ser	Ile	Ser	Thr	Gln	Ser	Val
65					70					75				80	
Leu	Ala	Ala	Gln	Met	Ala	Ala	Gln	Lys	Leu	Pro	Val	Ile	Gly	Gly	Ile
				85					90					95	
Ala	Ile	Pro	Asp	Leu	Lys	Ile	Asn	Leu	Pro	Ile	Phe	Lys	Gly	Leu	Asp
			100					105					110		
Asn	Val	Gly	Leu	Thr	Tyr	Gly	Ala	Gly	Thr	Met	Lys	Asn	Asp	Gln	Val
		115					120					125			
Met	Gly	Glu	Asn	Asn	Tyr	Ala	Leu	Ala	Ser	His	His	Val	Phe	Gly	Met
	130					135					140				
Thr	Gly	Ser	Ser	Gln	Met	Leu	Phe	Ser	Pro	Leu	Glu	Arg	Ala	Lys	Glu
145					150					155					160
Gly	Met	Glu	Ile	Tyr	Leu	Thr	Asp	Lys	Asn	Lys	Val	Tyr	Thr	Tyr	Val
				165					170					175	
Ile	Ser	Glu	Val	Lys	Thr	Val	Thr	Pro	Glu	His	Val	Glu	Val	Ile	Asp
			180					185					190		
Asn	Arg	Pro	Gly	Gln	Asn	Glu	Val	Thr	Leu	Val	Thr	Cys	Thr	Asp	Ala
		195					200					205			
Gly	Ala	Thr	Ala	Arg	Thr	Ile	Val	His	Gly	Thr	Tyr	Lys	Gly	Glu	Asn
	210					215					220				
Asp	Phe	Asn	Lys	Thr	Ser	Lys	Lys	Ile	Lys	Lys	Ala	Phe	Arg	Gln	Ser
225					230					235					240
Tyr	Asn	Gln	Ile	Ser	Phe										
				245											

<210> 8

<211> 198

<212> PRT

<213> Bacillus subtilis

<400> 8

Met	Lys	Lys	Val	Ile	Pro	Leu	Phe	Ile	Ile	Ala	Ala	Gly	Leu	Val	Ile
1			5					10					15		
Ala	Gly	Tyr	Gly	Gly	Phe	Lys	Leu	Ile	Asp	Thr	Asn	Thr	Lys	Thr	Glu
			20					25					30		
Gln	Thr	Leu	Lys	Glu	Ala	Lys	Leu	Ala	Ala	Lys	Lys	Pro	Gln	Glu	Ala
		35					40					45			
Ser	Gly	Thr	Lys	Asn	Ser	Thr	Asp	Gln	Ala	Lys	Asn	Lys	Ala	Ser	Phe
	50				55						60				
Lys	Pro	Glu	Thr	Gly	Gln	Ala	Ser	Gly	Ile	Leu	Glu	Ile	Pro	Lys	Ile
65					70					75				80	
Asn	Ala	Glu	Leu	Pro	Ile	Val	Glu	Gly	Thr	Asp	Ala	Asp	Asp	Leu	Glu
			85					90					95		
Lys	Gly	Val	Gly	His	Tyr	Lys	Asp	Ser	Tyr	Tyr	Pro	Asp	Glu	Asn	Gly
			100					105					110		
Gln	Ile	Val	Leu	Ser	Gly	His	Arg	Asp	Thr	Val	Phe	Arg	Arg	Thr	Gly
		115					120					125			
Glu	Leu	Glu	Lys	Gly	Asp	Gln	Leu	Arg	Leu	Leu	Leu	Ser	Tyr	Gly	Glu
	130					135					140				

Phe Thr Tyr Glu Ile Val Lys Thr Lys Ile Val Asp Lys Asp Asp Thr
 145 150 155 160
 Ser Ile Ile Thr Leu Gln His Glu Lys Glu Glu Leu Ile Leu Thr Thr
 165 170 175
 Cys Tyr Pro Phe Ser Tyr Val Gly Asn Ala Pro Lys Arg Tyr Ile Ile
 180 185 190
 Tyr Gly Lys Arg Val Thr
 195

<210> 9
 <211> 25
 <212> PRT
 <213> Staphylococcus aureus

<400> 9
 Glu Glu Asn Pro Phe Ile Gly Thr Thr Val Phe Gly Gly Leu Ser Leu
 1 5 10 15
 Ala Leu Gly Ala Ala Leu Leu Ala Gly
 20 25

<210> 10
 <211> 23
 <212> PRT
 <213> Staphylococcus aureus

<400> 10
 Gly Glu Glu Ser Thr Asn Lys Gly Met Leu Phe Gly Gly Leu Phe Ser
 1 5 10 15
 Ile Leu Gly Leu Ala Leu Leu
 20

<210> 11
 <211> 24
 <212> PRT
 <213> Staphylococcus sobrinus

<400> 11
 Asp Ser Ser Asn Ala Tyr Leu Pro Leu Leu Gly Leu Val Ser Leu Thr
 1 5 10 15
 Ala Gly Phe Ser Leu Leu Gly Leu
 20

<210> 12
 <211> 24
 <212> PRT
 <213> Enterococcus faecalis

<400> 12
 Glu Lys Gln Asn Val Leu Leu Thr Val Val Gly Ser Leu Ala Ala Met
 1 5 10 15
 Leu Gly Leu Ala Gly Leu Gly Phe
 20

<210> 13
<211> 23
<212> PRT
<213> Streptococcus pyogenes

<400> 13
Ser Ile Gly Thr Tyr Leu Phe Lys Ile Gly Ser Ala Ala Met Ile Gly
1 5 10 15
Ala Ile Gly Ile Tyr Ile Val
20

<210> 14
<211> 22
<212> PRT
<213> Listeria monocytogenes

<400> 14
Asp Ser Asp Asn Ala Leu Tyr Leu Leu Leu Gly Leu Leu Ala Val Gly
1 5 10 15
Thr Ala Met Ala Leu Thr
20

<210> 15
<211> 5
<212> PRT
<213> Staphylococcus aureus

<400> 15
Arg Arg Arg Glu Leu
1 5

<210> 16
<211> 9
<212> PRT
<213> Staphylococcus aureus

<400> 16
Arg Arg Asn Lys Lys Asn His Lys Ala
1 5

<210> 17
<211> 5
<212> PRT
<213> Staphylococcus sobrinus

<400> 17
Arg Arg Lys Gln Asp
1 5

<210> 18
<211> 7
<212> PRT
<213> Enterococcus faecalis

<400> 18
Lys Arg Arg Lys Glu Thr Lys
1 5

<210> 19
<211> 5
<212> PRT
<213> Streptococcus pyogenes

<400> 19
Lys Arg Arg Lys Ala
1 5

<210> 20
<211> 8
<212> PRT
<213> Actinomyces viscosus

<400> 20
Lys Arg Arg His Val Ala Lys His
1 5

<210> 21
<211> 5
<212> PRT
<213> Streptococcus agalactiae

<400> 21
Lys Arg Arg Lys Ser
1 5

<210> 22
<211> 6
<212> PRT
<213> Streptococcus pyogenes

<400> 22
Lys Arg Lys Glu Glu Asn
1 5

<210> 23
<211> 5
<212> PRT
<213> Mutated derived from streptococcus pyogenes

<400> 23
Arg Arg Arg Glu Ser
1 5

<210> 24
<211> 5
<212> PRT

```

    <213> Mutated derived from streptococcus pyogenes

    <400> 24
Arg Arg Arg Ser Leu
 1          5

    <210> 25
    <211> 5
    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 25
Arg Arg Ser Glu Leu
 1          5

    <210> 26
    <211> 5
    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 26
Arg Ser Arg Glu Leu
 1          5

    <210> 27
    <211> 5
    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 27
Ser Arg Arg Glu Leu
 1          5

    <210> 28
    <211> 5
    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 28
Arg Arg Ser Ser Ser
 1          5

    <210> 29
    <211> 5
    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 29
Arg Ser Arg Ser Ser
 1          5

    <210> 30
    <211> 5

```

```

    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 30
Ser Arg Arg Ser Ser
1          5

    <210> 31
    <211> 19
    <212> PRT
    <213> Mutated derived from streptococcus pyogenes

    <400> 31
His His His His His His Ala Gln Ala Leu Glu Pro Thr Gly Glu Glu
1          5          10          15
Asn Pro Phe

    <210> 32
    <211> 29
    <212> DNA
    <213> Staphylococcus aureus

    <400> 32
aaggattcaa aaggagcggg atacattgc
29

    <210> 33
    <211> 29
    <212> DNA
    <213> Staphylococcus aureus

    <400> 33
aaggatccta ccttttcctc tagctgaac
29

    <210> 34
    <211> 283
    <212> PRT
    <213> Streptococcus pneumoniae srtA

    <400> 34
Met Ser Arg Thr Lys Leu Arg Ala Leu Leu Gly Tyr Leu Leu Met Leu
1          5          10          15
Val Ala Cys Leu Ile Pro Ile Tyr Cys Phe Gly Gln Met Val Leu Gln
20          25          30
Ser Leu Gly Gln Val Lys Gly His Ala Thr Phe Val Lys Ser Met Thr
35          40          45
Thr Glu Met Tyr Gln Glu Gln Gln Asn His Ser Leu Ala Tyr Asn Gln
50          55          60
Arg Leu Ala Ser Gln Asn Arg Ile Val Asp Pro Phe Leu Ala Glu Gly
65          70          75          80
Tyr Glu Val Asn Tyr Gln Val Ser Asp Asp Pro Asp Ala Val Tyr Gly
85          90          95
Tyr Leu Ser Ile Pro Ser Leu Glu Ile Met Glu Pro Val Tyr Leu Gly

```

Ala	Asp	Tyr	His	His	Leu	Gly	Met	Gly	Leu	Ala	His	Val	Asp	Gly	Thr
	115						120						125		
Pro	Leu	Pro	Leu	Asp	Gly	Thr	Gly	Ile	Arg	Ser	Val	Ile	Ala	Gly	His
	130						135					140			
Arg	Ala	Glu	Pro	Ser	His	Val	Phe	Phe	Arg	His	Leu	Asp	Gln	Leu	Lys
145					150					155					160
Val	Gly	Asp	Ala	Leu	Tyr	Tyr	Asp	Asn	Gly	Gln	Glu	Ile	Val	Glu	Tyr
				165					170					175	
Gln	Met	Met	Asp	Thr	Glu	Ile	Ile	Leu	Pro	Ser	Glu	Trp	Glu	Lys	Leu
			180					185					190		
Glu	Ser	Val	Ser	Ser	Lys	Asn	Ile	Met	Thr	Leu	Ile	Thr	Cys	Asp	Pro
	195						200					205			
Ile	Pro	Thr	Phe	Asn	Lys	Arg	Leu	Leu	Val	Asn	Phe	Glu	Arg	Val	Ala
	210					215					220				
Val	Tyr	Gln	Lys	Ser	Asp	Pro	Gln	Thr	Ala	Ala	Val	Ala	Arg	Val	Ala
225					230					235					240
Phe	Thr	Lys	Glu	Gly	Gln	Ser	Val	Ser	Arg	Val	Ala	Thr	Ser	Gln	Trp
				245					250					255	
Leu	Tyr	Arg	Gly	Leu	Val	Val	Leu	Ala	Phe	Leu	Gly	Ile	Leu	Phe	Val
			260					265					270		
Leu	Trp	Lys	Leu	Ala	Arg	Leu	Leu	Arg	Gly	Lys					
		275					280								

<210> 35
 <211> 296
 <212> PRT
 <213> Streptococcus pneumoniae srtB

<400> 35

Met	Asp	Asn	Ser	Arg	Arg	Ser	Arg	Lys	Lys	Gly	Thr	Lys	Lys	Lys	Lys
1				5					10					15	
His	Pro	Leu	Ile	Leu	Leu	Leu	Ile	Phe	Leu	Val	Gly	Phe	Ala	Val	Ala
			20					25					30		
Ile	Tyr	Pro	Leu	Val	Ser	Arg	Tyr	Tyr	Tyr	Arg	Ile	Ser	Asn	Glu	Val
		35					40					45			
Ile	Lys	Glu	Phe	Asp	Glu	Thr	Val	Ser	Gln	Met	Asp	Lys	Ala	Glu	Leu
	50					55					60				
Glu	Glu	Arg	Trp	Arg	Leu	Ala	Gln	Ala	Phe	Asn	Ala	Thr	Leu	Lys	Pro
65					70					75					80
Ser	Glu	Ile	Leu	Asp	Pro	Phe	Thr	Glu	Gln	Glu	Lys	Lys	Lys	Gly	Val
				85					90					95	
Ser	Glu	Tyr	Ala	Asn	Met	Leu	Lys	Val	His	Glu	Arg	Ile	Gly	Tyr	Val
			100					105					110		
Glu	Ile	Pro	Ala	Ile	Asp	Gln	Glu	Ile	Pro	Met	Tyr	Val	Gly	Thr	Ser
		115					120					125			
Glu	Asp	Ile	Leu	Gln	Lys	Gly	Ala	Gly	Leu	Leu	Glu	Gly	Ala	Ser	Leu
	130					135						140			
Pro	Val	Gly	Gly	Glu	Asn	Thr	His	Thr	Val	Ile	Thr	Ala	His	Arg	Gly
145					150					155					160
Leu	Pro	Thr	Ala	Glu	Leu	Phe	Ser	Gln	Leu	Asp	Lys	Met	Lys	Lys	Gly
				165					170					175	
Asp	Ile	Phe	Tyr	Leu	His	Val	Leu	Asp	Gln	Val	Leu	Ala	Tyr	Gln	Val

Asp	Gln	Ile	Val	Thr	Val	Glu	Pro	Asn	Asp	Phe	Glu	Pro	Val	Leu	Ile
		180						185					190		
Gln	His	Gly	Glu	Asp	Tyr	Ala	Thr	Leu	Leu	Thr	Cys	Thr	Pro	Tyr	Met
		195						200					205		
Ile	Asn	Ser	His	Arg	Leu	Leu	Val	Arg	Gly	Lys	Arg	Ile	Pro	Tyr	Thr
		210						215					220		
Ala	Pro	Ile	Ala	Glu	Arg	Asn	Arg	Ala	Val	Arg	Glu	Arg	Gly	Gln	Phe
				225		230				235				240	
Trp	Leu	Trp	Leu	Leu	Leu	Gly	Ala	Met	Ala	Val	Ile	Leu	Leu	Leu	Leu
				245				250						255	
Tyr	Arg	Val	Tyr	Arg	Asn	Arg	Arg	Ile	Val	Lys	Gly	Leu	Glu	Lys	Gln
		260						265						270	
Leu	Glu	Gly	Arg	His	Val	Lys	Asp							285	
		275						280							
		290						295							

<210> 36
 <211> 304
 <212> PRT
 <213> Streptococcus pneumoniae srtC

Met	Leu	Ile	Lys	Met	Val	Lys	Thr	Lys	Lys	Gln	Lys	Arg	Asn	Asn	Leu
				5				10					15		
Leu	Leu	Gly	Val	Val	Phe	Phe	Ile	Gly	Met	Ala	Val	Met	Ala	Tyr	Pro
				20				25					30		
Leu	Val	Ser	Arg	Leu	Tyr	Tyr	Arg	Val	Glu	Ser	Asn	Gln	Gln	Ile	Ala
				35				40					45		
Asp	Phe	Asp	Lys	Glu	Lys	Ala	Thr	Leu	Asp	Glu	Ala	Asp	Ile	Asp	Glu
				50				55				60			
Arg	Met	Lys	Leu	Ala	Gln	Ala	Phe	Asn	Asp	Ser	Leu	Asn	Asn	Val	Val
				65				70				75			80
Ser	Gly	Asp	Pro	Trp	Ser	Glu	Glu	Met	Lys	Lys	Lys	Gly	Arg	Ala	Glu
				85				90						95	
Tyr	Ala	Arg	Met	Leu	Glu	Ile	His	Glu	Arg	Met	Gly	His	Val	Glu	Ile
				100				105					110		
Pro	Val	Ile	Asp	Val	Asp	Leu	Pro	Val	Tyr	Ala	Gly	Thr	Ala	Glu	Glu
				115				120					125		
Val	Leu	Gln	Gln	Gly	Ala	Gly	His	Leu	Glu	Gly	Thr	Ser	Leu	Pro	Ile
				130				135					140		
Gly	Gly	Asn	Ser	Thr	His	Ala	Val	Ile	Thr	Ala	His	Thr	Gly	Leu	Pro
				145				150					155		160
Thr	Ala	Lys	Met	Phe	Thr	Asp	Leu	Thr	Lys	Leu	Lys	Val	Gly	Asp	Lys
				165				170						175	
Phe	Tyr	Val	His	Asn	Ile	Lys	Glu	Val	Met	Ala	Tyr	Gln	Val	Asp	Gln
				180				185					190		
Val	Lys	Val	Ile	Glu	Pro	Thr	Asn	Phe	Asp	Asp	Leu	Leu	Ile	Val	Pro
				195				200					205		
Gly	His	Asp	Tyr	Val	Thr	Leu	Leu	Thr	Cys	Thr	Pro	Tyr	Met	Ile	Asn
				210				215					220		
Thr	His	Arg	Leu	Leu	Val	Arg	Gly	His	Arg	Ile	Pro	Tyr	Val	Ala	Glu
				225				230						240	
Val	Glu	Glu	Glu	Phe	Ile	Ala	Ala	Asn	Lys	Leu	Ser	His	Leu	Tyr	Arg
								235							

				245					250					255		
Tyr	Leu	Phe	Tyr	Val	Ala	Val	Gly	Leu	Ile	Val	Ile	Leu	Leu	Trp	Ile	
			260					265					270			
Ile	Arg	Arg	Leu	Arg	Lys	Lys	Lys	Lys	Gln	Pro	Glu	Lys	Ala	Leu	Lys	
		275					280					285				
Ala	Leu	Lys	Ala	Ala	Arg	Lys	Glu	Val	Lys	Val	Glu	Asp	Gly	Gln	Gln	
	290					295					300					